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Chapter 1: The Obesity Epidemic and Eating Disorders 
Introduction 
The obesity epidemic around the globe has risen 3-fold or more over the past 
20 years; currently, one billion adults are overweight with 300 million of them being 
obese1.  In several developed countries the cost of health related issues associated 
with obesity encompasses 2-6% of total health related expenses, with some areas 
being as high as 7%2. Elucidation of mechanisms that regulate food intake and body 
weight will allow development of novel treatments to alleviate the severity of health 
care costs and improve the quality of life for the obese. In addition, twenty-two 
million children under the age of 5 are classified as obese, with the number having 
doubled since 19802. Obesity results from an imbalance between food intake and 
energy expenditure or a lack of physiological feedback required to maintain an 
appropriate level of food intake and body weight3.  Lesions of the lateral nuclei of the 
hypothalamus result in obesity and lesions of either the ventromedial or 
paraventricular nuclei result in an abnormal increase in food intake, suggesting that 
the hypothalamus exerts significant control in regulation of food intake and body 
weight4,5. Therefore, we propose to examine hypothalamic gene expression during 
development of obesity in a genetically selected fat and lean animal model.   
Eating disorders often arise from the following three factors: 1) environmental 
influences alone, 2) genetics alone or 3) environment acting on genetic predisposition 
that increases an individual’s risk for expressing an eating disorder. Examples of 
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eating disorders are obesity, anorexia nervosa, bulimia nervosa and binge eating 
disorder6,7. Eating disorders encompass disturbances in energy balance which are 
caused by or result in food intake alterations that are aberrant or compulsive in nature 
and genetically are polygenic and multifactorial (a number of genes each with small 
effects that contribute to the severity of the phenotype)3. Obesity is considered an 
eating disorder because over eating (hyperphagia) is one trait associated with the 
phenotype with intake usually being compulsive in nature, not easily controlled and 
initiated by cues in the surrounding environment. Anorexia and bulimia are similar to 
obesity in that they have extremes in food intake and obsessions6. Increased or 
decreased food intake and obsessive behaviors resemble addictive behavior in that it 
is modulated by neurochemical abnormalities and the risk for developing such 
disorders is most often determined by an underlying genetic predisposition that 
increases an individual’s susceptibility to develop the disorder. It has been shown that 
alterations in neurotransmitters, neuropeptides and neuroendocrine functions can 
contribute to these differences8. 
Obesity, hereditability and genetics  
Hereditability is a factor associated with obesity since the likelihood of 
developing this phenotype increases when a biological relative is obese: twins, 50-
80%; intermediate family, 30-50%; adoption, 10-30%9.  Genetic implications 
associated with obesity are further supported by the fact that the phenotype appears as 
a continuously distributed phenotype, providing evidence that the severity of the 
phenotype depends on which alleles segregate together, as well as the number of 
genes associated with the phenotype10-18. Similar to humans, hereditability of 
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adiposity is also present in the chicken model of obesity19. The Fat and Lean lines 
used in our studies are an ideal model for investigating neural gene expression 
regulating food intake, metabolism, and body weight in the hypothalamus since 
intercrossing of the two lines results in a normal distribution of these phenotypes, 
indicating that the phenotypes arise because of quantitative traits and not from a 
spontaneous, deletional or point mutation19,20.   
Quantitative traits are phenotypes that arise from genetic influences that reside 
on multiple genes, and a model such as this is a powerful tool to investigate genetic 
interactions19.  One rat model utilizing quantitative traits was bred to be susceptible to 
dietary-induced obesity (DIO) or to be diet resistant (DR) for developing obesity, 
allowing investigation of a rodent model to determine how environment and genotype 
interact to influence the susceptibility for obesity21.  To our knowledge this is the only 
known quantitative trait model of obesity present in the rodent species. Thus, the Fat 
and Lean lines of chicken might currently be the only known animal model of obesity 
arising from genotype alone, more specifically, adiposity that develops independently 
of environmental influences.  We strongly believe that the chicken is an excellent but 
under utilized model organism for studies of weight regulation as well as an ideal 
model to investigate genetic interactions that influence expression of the obese or lean 
phenotypes. 
The Brain and Obesity 
The hypothalamus is quite important in modulating energy balance throughout 
the entire animal, but it is not the only brain region implicated in the control of eating 
disorders. For example, intrinsic activation, arising from internal stimuli like hunger, 
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activates the hypothalamus, insula, amygdala, anterior cingulated, thalamus and 
brainstem22.  On the other hand, satiety activates the orbitofrontal cortex (OFC), 
bilateral occipital cortex, inferior temporal cortex and posterior temporal region. 
Extrinsic factors, such as palatable foods, activate the amygdala and OFC22 and have 
been shown to also activate the gustatory cortex, striatum, midbrain, subcallosal 
region and caudomedial orbitofrontal cortex7.   
So, how do these brain regions differ in an obese relative to a non-obese 
individual? It has been suggested that obese individuals have decreased electrical 
activation in the hypothalamus after a meal, relative to a lean individual7. The 
activation in the prefrontal cortex and the limbic/paralimbic areas also demonstrate 
differences between obese and lean individuals. For example, the prefrontal cortex 
influences other areas of the brain in order to suppress food intake, with the prefrontal 
cortex actually suppressing activity in the hypothalamus (i.e. lateral hypothalamus), 
thalamus, limbic system (olfactory cortex, amygdala, and hippocampus) and the basal 
ganglia23.  Obese individuals differ from lean individuals given that they have 
increased activation of the prefrontal cortex and decreased activation in the 
limbic/paralimbic system. To elaborate a bit further, it has been shown that after a 
meal, posterior cingulated, amygdala, insular cortex and primary ingestive cortex 
activity is different between lean and obese individuals23 and strikingly, this activity 
in 2 out of the 4 regions (the posterior cingulate and the amygdala) could return to 
normal if obese individuals returned to normal weight. Not all brain regions return to 
normal, it suggesting that the areas that remain abnormal might contribute to the 
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rebound effect of weight gain that most obese individuals experience after losing 
weight.   
The nucleus accumbens and the ventral tagmental areas have both been 
implicated in eating disorders and addiction, which may function to reinforce the 
eating disorder through positive rewards via dopamine receptors24.  The ventral 
striatum and the prefrontal cortex are regions known to regulate incentive learning 
and reinforcement mechanisms associated with positive rewards through dopamine 
receptors25. However, it should be noted that addictive behaviors to drugs, termed 
unnatural since this is a learned behavior, are different than addictive behaviors to 
food due to the nature of the reward; food addiction is termed natural since the 
behavior is driven by internal physiological cues. It is the natural rewards, like food, 
that may work independent of dopaminergic signals in this area, but the unnatural 
rewards, induced by drugs, work via dopaminergic signaling pathways. This will be 
described in more detail later. Thus, alterations in dopaminergic working in other 
brain regions than this and endorphin signaling in these brain regions may give rise to 
the eating disorders that have addictive properties. 
 Anorexia and bulimia involve alteration to the serotonergic signaling pathway 
in the frontal, temporal, cingulated and parietal regions6.  Although both eating 
disorders have alterations in the same signaling system, there are differences between 
the two.  First, Kaye et.al.6 (2005) demonstrated similarities between anorexia and 
bulimia by showing reduced serotonin 2A receptor activity in the subgenual 
cingulate, mesial temporal (amygdala), and parietal cortical regions. Differences 
between anorexic and bulimic individuals were then demonstrated by showing that 
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serotonin 1A receptor functions in bulimia, but it is the 2A receptor that functions in 
anorexia6.  The brain region that likely modulates both the anorexic and bulimic 
phenotype is likely the amygdala signaling pathway to the cingulate. This alteration 
in serotonin signaling relates to addictive behavior, given that it can also influence 
extremes of impulse control, perhaps giving rise to a genetic susceptibility that might 
influence the development of an eating disorder26 through addictive processes that 
resemble reward deficiency syndrome24.  
Obesity, food intake and neuropeptides in the hypothalamus  
The hypothalamus is a primary modulator of metabolism, food intake and body 
weight.  It has been previously shown that ablating specific nuclei within the 
hypothalamus can result in altered food intake4,5.  For example, hunger has been 
associated with the lateral nuclei and satiety with both the paraventricular (PVN) and 
ventromedial (VMH) nuclei.  Similar to mammals, lesions in the VMH of the  
chickens result in an obese phenotype27.  Given this, it is probable that neural 
circuitry regulating food intake and body weight in the hypothalamus is 
evolutionarily conserved. Hypothalamic nuclei contain either orexigenic/anabolic 
neuropeptides (i.e. Neuropeptide Y, NPY; Agouti-related protein AGRP) or 
anorexigenic/catabolic neuropeptides (i.e. proopiomelanocortin, POMC) and regulate 
body weight, metabolism and food intake via expression of these neuropeptides. For 
example, increasing leptin levels, a hormone released from adipose tissue, increases 
activity and neuropeptides located in orexigenic neurons of the PVN, result in 
increased food intake8.   
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Schwartz et.al. (2000) reviewed how this neuronal circuitry functions.  
Normally, decreased leptin, as well as insulin, inhibits POMC signaling leading to a 
decrease in α-melanocyte-stimulating hormone (αMSH) levels, a product of POMC 
cleavage by POMC converting enzymes28.  Decreased food intake results when 
αMSH decreases melanocortin (MC) receptor signaling, since αMSH is a ligand for 
the Melanocortin-4 receptor (MC4R). Working through another pathway, the 
decreased leptin and insulin levels activate the NPY/AGRP neuron by increasing 
production and release of AGRP.  This results in increased food intake since AGRP is 
an inverse agonist for MC4R, preventing further binding of αMSH to the MC 
receptor and resulting in the opposite phenotype 2 9. The melanocortin pathway is 
unique in the sense it has a naturally occurring agonist (αMSH) and inverse agonist 
(AGRP) that serve to modulate signaling.  
Brain-Derived Neurotrophic Factor (BDNF) and Obesity  
 One neuropeptide we would like to focus on is BDNF because it has been 
implicated in the etiology of eating disorders30-35.  BDNF mutant mice (+/-) were first 
created to investigate its role in sensory neuron development36.  However, it was 
noticed that both obesity and hyperphagia were phenotypes present in BDNF 
haploinsufficient mice32,34.  Of even greater interest, conditional mutants lacking 
BDNF only in the brain after birth, mutants that eliminate confounding 
developmental effects, demonstrate an even greater obesity than the haploinsufficient 
mice, suggesting that modulation of body weight is directly related to BDNF 
expression in the brain35.  BDNF has also been suggested to be part of a mechanism 
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underlying mature-onset obesity due to increased intake, implying that it may play a 
role in the development of obesity over time due to hyperphagic intake30.    
Altered levels of BDNF have been associated with anorexia, obesity, 
bulimia31,37, and alcoholism38.  Three BDNF variants and a polymorphism were 
identified by screening patients with obesity, eating disorders and attention deficit 
hyperactivity disorder31. Mechanisms that contribute to obesity and alcoholism appear 
to be influenced by decreased BDNF expression, since it has been shown that 
decreased levels of BDNF lead to development of obesity35 and increased behavioral 
response to alcohol exposure38. On the other hand, opposite changes in BDNF 
expression were observed in humans with obesity and anorexia, with decreased levels 
in obese humans and increased levels in anorexics37. It is plausible that the molecular 
signals that respond to increased or decreased levels of BDNF could contribute to the 
development of these specific phenotypes.  For example, endorphin levels are 
increased in an anorexic state39 and this increase in opioids could be interacting with 
or modulating BDNF expression.  This idea has been supported since an opioid 
receptor agonist increased levels of BDNF40. In addition to this, BDNF interacts with 
other signaling pathways to mediate these addictive phenotypes. For example, BDNF 
has been shown to regulate expression of the dopamine 3 receptor, a receptor in the 
nucleus accumbens that has been associated with addictive behaviors41. Lastly, 
polymorphisms and variants in the BDNF gene are associated with development of 
the obese, anorexic or bulimic phenotype31.  However, it remains to be determined 
exactly how these polymorphisms and variants contribute to development of the 
phenotype.  For example, are they contributing independent of environmental 
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influences or do these variants create a genetic susceptibility that induces the 
phenotype after experience. 
It is plausible that BDNF might induce a phenotype only after experience, 
given that Fox and Byerly30 demonstrated that BDNF haploinsuffecient mice 
(heterozygous for the BDNF gene) do not exhibit hyperphagic intake (increased 
intake) or obesity if they are fed a well balanced diet as young animals, but at 8 
months of age the animals over consume food and are obese regardless of the diet 
they consume.  Even though young BDNF haploinsufficient mice do not over 
consume food on a well balanced diet until later in life, environmental influences can 
induce the hyperphagic intake in the young animals if they are given a high-fat diet. 
However, the obese phenotype still did not develop at the earlier age even when the 
high-fat diet was over consumed for a two week period of time. Given this, it is 
plausible that the high-fat diet and the decreased BDNF expression interact with 
another signaling system that induced hyperphagic intake without the obese 
phenotype being present, such as the melanocortin system42. 
Neuroendocrine system and obesity 
Thyroid Hormone  
 Thyroid hormones are produced in the thyroid gland, with thyroxine (T4) and 
low levels of triiodothyronine (T3) forming within thyroglobulin43. Thyroid hormones 
are known to modulate many aspects of metabolism, primarily by increasing basal 
metabolic rate after fasting or refeeding. This process contributes to energy 
homeostasis by matching energy intake and energy expenditure over time. If thyroid 
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hormones are in excess (hyperthyroid), this leads to negative energy balance and 
weight loss because the basal metabolic rate is increased relative to energy intake. 
When thyroid hormone levels are minimal (hypothyroid) this results in weight gain 
because basal metabolic rate is decreased relative to energy intake resulting in a 
positive energy balance. Interestingly, euthyroid morbidly obese individuals are not 
able to maintain this balance and have an overall positive energy balance despite 
slightly elevated levels of T344. Thyroid hormones are also considered tissue growth 
factors because they contribute to such things as neuronal development and protein 
synthesis.  
Thyroid hormone deiodinases are enzymes that convert T4 to T3, as well as 
inactivate the thyroid hormones45. Type I deiodinase is present in the periphery and 
converts T4 to T3, Type II deiodinase is in the brain and converts T4 to T3 with 1000 
times greater affinity than Type I46. The TRH neurons located in the paraventricular 
nucleus (PVN) of the hypothalamus respond to T3 levels either in the periphery or 
from other brain regions, since there is very low, if any, Type II deiodinase present in 
the PVN47. Tanycytes are glia located along the inferior portion of the third ventricle 
and are innervated by peptidergic and aminergic neurons48-50. Tanycyte cells are 
believed to be the structure that links ventricular cerebrospinal fluid (CSF) to the 
arcuate nucleus of the hypothalamus, suggesting that this anatomical structure is key 
in linking neuroendocrine events with CSF49. Tanycytes also have a high 
concentration of Type II deiodinase and are thought to be the primary source in the 
brain signaling to TRH neurons by converting T4 to T3, as well as the arcuate nucleus 
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and in lower concentrations in the ventromedial nucleus, dorsomedial nucleus and 
lateral hypothalamus51.  
Brain-Derived Neurotrophic Factor and Thyroid Hormone  
Hyperthyroidism has been associated with increased food intake.  There is 
currently a small body of literature providing evidence that BDNF may interact with 
or be modulated by the hypothalamic-pituitary-thyroid axis. Since decreased levels of 
BDNF and increased levels of thyroid hormone (T3) have both been associated with 
hyperphagia, we are proposing to further investigate the interaction between BDNF 
and the HPT axis.  It has previously been shown that hypothalamic neurons treated 
with BDNF enhance the expression of thyrotropin releasing hormone (TRH) 
mRNA52. Adult neurons in the band of Broca treated with T3 have suppressed BDNF 
expression53. Recently it has been shown that BDNF can regulate expression of pre-
pro-TRH in the PVN54.  Additionally, this interaction may also involve neuropeptides 
known to modulate food intake and energy expenditure, such as NPY.  Increased 
levels of T3 result in increased expression of NPY, along with CART and POMC55, 
and BDNF and TrkB signaling have also been demonstrated to modulate expression 
of NPY in the hypothalamus56.   
Glucocorticoids, leptin and insulin 
Glucocorticoids are hormones that regulate many different aspects of 
physiology altered by stress. The cortex of the adrenal gland is responsible for 
synthesizing glucocorticoids, as well as aldosterone. One physiological parameter 
modulated by glucocorticoids is metabolism, stimulating gluconeogenesis to maintain 
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energy balance, under chronic food and fluid deprivation. Glucocorticoids modulate 
expression of CRH levels in the hypothalamus, due to negative feedback, and 
excessive glucocorticoid levels result in hyperglycemia, insulin insensitivity, weight 
gain, and obesity43. 
Insulin was the first hormone identified to reduce food intake57.  Another 
signal that also reduces food intake is Leptin, which is released from adipocytes. Both 
of these hormones circulate at levels that correspond to the amount of adipose tissue 
and are referred to as adiposity signals8. These adiposity signals modulate 
neuropeptide gene expression in the hypothalamus by suppressing anabolic signals 
and increasing catabolic neuropeptide signals. The increased levels of leptin and 
insulin result in decreased NPY and AGRP neuropeptide levels with a simultaneous 
increase in POMC levels in the arcuate nucleus of hypothalamus.  For example, this 
decreased NPY/AGRP signals result in decreased production of NPY and decreased 
release of NPY onto neurons in the PVN, resulting in decreased food intake. This 
mechanism would normally serve to modulate energy balance by subsequently 
decreasing plasma insulin, leptin and body weight58, but malfunctions in the signaling 
often occur in individuals with an obese phenotype. 
  Glucocorticoids are another hormone that modulate neuropeptide signaling in 
the hypothalamus, such as NPY/AGRP and POMC.  Increased levels of 
glucocorticoids trigger the following responses in the brain: 1) decreased CRH 
expression due to negative feedback43, 2) altered activity of POMC neurons 
responding to changes in leptin and insulin levels59,60, 3) and if glucocorticoids are 
chronically in excess adiposity signals will be altered, resulting in increased 
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lipogenesis, decreased lipolysis, decreased insulin sensitivity (due to decreased 
gluconeogenesis) and increased glucose utilization43.  Glucocorticoids are known to 
functionally antagonize some of insulin’s peripheral effects with decreased levels of 
glucocorticoids resulting in increased insulin sensitivity61.  
Brain-Derived Neurotrophic Factor and Glucocorticoids  
 BDNF has been shown to interact with the hypothalamic-pituitary-
adrenocortical (HPA) system. The Val66Met polymorphism in the BDNF gene has 
been associated with impaired glucose metabolism and the anorexic phenotype62,63 as 
well as the HPA axis dysregulation in depressed patients64. However, the majority of 
the focus is on BDNF regulation in the hippocampus in relation to stress and 
learning65-67. Very little research focuses on BDNF expression in the hypothalamus, 
but it has been shown that immobilization stress does increase BDNF mRNA and 
protein expression in the hypothalamus68-70. 
 
Neurotransmitters and Eating disorders 
Eating disorders include obsessive thoughts and a compulsion to consume, 
similar to drug cravings71 and eating disorders are often co-expressed with addictive 
behaviors in this form.  Compulsive eating stimulates the reward pathway, the 
dopamine pathway, similar to drugs of abuse24.  However, addictive mechanisms for 
drugs may function differently from addictive behavior associated with food intake 
since there are two types of rewards that interact with this pathway, natural and 
unnatural rewards.  Natural rewards involve satisfaction of physiological drive, such 
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as food, sex and other pleasurable activities, whereas unnatural rewards are learned, 
such as drugs, gambling and alcohol. The differences between individuals that may 
cause them to seek out one type of behavior over the other may be attributable to a 
genetic component that I will discuss later, as well as dopaminergic signaling in 
different brain regions. 
Dopamine 
Gene-environment interactions can also increase the likelihood to develop an 
eating disorder, but presently relatively few studies have examined this.  
Environmental influences can alter responses to food cues, cognition, emotion, drive 
and reward in the following circumstances: 1) television ads or billboards may 
activate the drive to seek the rewarding aspects of food72 and 2) childhood 
maltreatment may induce over consumption and obesity73. Cues can induce 
behavioral stimuli through operant or classical conditioning and can be associated 
with palatable foods or addictive drugs.  These cues may act on the Dopamine system 
to predict rewards by increasing the behavioral response necessary for obtaining the 
reward25. 
The Dopamine reward incentive pathway, as well as the opioid signaling 
pathway, may contribute toward compulsive overeating in obese individuals by 
reinforcing the behavior, thus contributing toward repetitive behavior.  It is also likely 
that environmental cues may have activated the expression of the disorder due to a 
genetic risk/susceptibility for inducing the compulsive overeating. For example, it has 
been shown that abusive or neglectful situations could serve to trigger events that lead 
to this behavior and phenotype.  The association between childhood trauma and 
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severe obesity was examined in extremely obese patients about to undergo bariatric 
surgery, and 69% of obese patients self-reported childhood maltreatment, suggesting 
a positive correlation between the two73. 
 Other environmental factors that could act on the genetic susceptibility are 
natural rewards and drugs of abuse since they both activate the dopaminergic system, 
however activating this system is not essential for ‘liking’ a food74. Dopamine 
deficient mice, lacking the ability to make dopamine, have a preference for the sweet 
tastes of sucrose as demonstrated by increased lick rates when they gained exposure 
to the sweet source74, suggesting that the sweet taste reward reinforces behavior 
independently of dopaminergic signaling. However, in unnatural rewards that involve 
addiction towards drugs of abuse, dopaminergic signaling is a key pathway involved 
with the addictive behavior.  Perhaps instead of working through the dopamine 
system this ‘liking’ of food functions through the opioidergic or serotonergic 
signaling processes that I will explain below.  
The reward pathway (i.e. the dopamine (DA) pathway) has been shown to 
have a significant genetic component involving genetic and environmental influences 
that contribute to behavioral choices.  It has been suggested that DA may regulate 
anticipation of a given reward, more so than mechanisms that respond to receiving the 
reward itself.  The dopamine D2 receptor (DRD2) may play a large role in heritability 
of the impulsivity, appetite and reward aspect of eating disorders. Two 
polymorphisms of this gene have been associated with increased BMI and 
obesity24,75, with expression of DRD2 being decreased in individuals with obesity, 
similar to reward deficiency syndrome which also underlies alcoholism76.  Not 
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surprisingly, this gene has also been associated with many other behavioral disorders 
like alcoholism, smoking, personality, Tourette syndrome and gambling.  However, it 
is the variants and polymorphisms of this gene and how their alleles pair together that 
give rise to the varied phenotypes attributable to this one gene.   
Opioidergic Signaling 
Endorphins are associated with aspects of food intake consumption like being 
satisfied, satiated and aspects of reward (i.e., sedation, rest and bliss)24, as well as 
increasing food intake when an agonist is given and decreasing food intake when an 
antagonist is given77. Endorphins are also associated with determining palatability of 
food and how an individual feels when they consume the food78 and might be 
involved with eating disorders involving hyperphagic intake, similar to obesity, 
bulimia and binge eating disorder. Sugar-dependent animals show similar alterations 
in dopamine and opioid mRNA levels in the ventral striatum as morphine-dependent 
animals, suggesting that neuronal functions might be similar for both types of 
addiction in this brain region79. The ventral striatum also contains opioid receptors 
(mu, delta and kappa) that regulate palatability and the positive response one feels 
after consuming some foods, and in the nucleus accumbens the opioid receptor 
functions to regulate sucrose, salt and saccharin appetite in water-deprived animals25. 
Desiring the acquisition of the positive feeling associated with consuming certain 
food may be strong enough to then bypass the energy balance set point determined by 
the arcuate nucleus of the hypothalamus25 and ultimately result in body weight that is 
greater than the normal set point.   
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Demonstrating a relationship between food intake and opioid levels, highly 
palatable foods appear to produce an analgesic effect in human females eating 
chocolate chip cookies compared to an unpalatable food, thereby providing further 
evidence supporting the positive effect opioids can have when certain foods are 
consumed71,80. Also, bulimic individuals have been shown to decrease the binging 
episode if they are administered an opiate blocker, naloxene71,81. Lastly, it has also 
been suggested that opioidergic signaling has altered functions in anorexia. For 
example, increased levels of β-endorphin were measured in the anorexic state77. 
Perhaps, it is the increased level of endorphins that induce a pleasant feeling in the 
anorexic individual, providing a possible explanation for why they do not feel as good 
when they consume food or increase weight because this would lead to a decrease in 
the amount of endorphins. 
Serotonergic Signaling 
Brain serotonin signaling interacts with many different systems, such as the 
opioid system and brain-derived neurotrophic factor, which have been associated with 
depression, consumption of foods for taste and pleasure, obesity and food cravings.  
Loss of the serotonin 2C receptor leads to the development of obesity, whereas 
increasing the serotonin precursor, tryptophan, is thought to be associated with 
carbohydrate cravings 71. Given that low levels of serotonin are expressed in 
depressed individuals, it is plausible that carbohydrate consumption that leads to 
increased serotonin precursor production would drive individuals to consume more 
carbohydrates in order to self medicate because it results in a pleasurable feeling, 
perhaps explaining why obesity and depression are often co-expressed together.  
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It has been observed that anorexic and bulimic individuals have altered 
serotonergic functioning in the frontal, cingulated, temporal and parietal regions of 
the brain6.  Kaye et.al.6 have reported that different serotonin receptor types are 
associated with anorexia and bulimia. Anorexic individuals have reduced 5-HT 2A 
receptor functions, whereas bulimic individuals have increased 5-HT1A receptor 
function. Further evidence to support the role of serotonin in bulimia demonstrated 
that an increased urge to binge occurs when bulimic women were given a tryptophan 
deficient drink71. 
From the Macroscopic and Microscopic to Perception and Cognition 
 Eating disorders are a complex disease arising from environmental as well as 
physiological cues. It is most likely the physiological enforcement (i.e. satiety, 
reward, sensations induced by the release of opioids) following environmental cues 
such as visual or smell cues, billboards, driving past fast food places or restaurants 
that alter our neurochemistry to drive our behaviors and thoughts. At some point the 
environmental and physiological cues integrate to produce phenotypes and behavioral 
patterns, but we do not know what the mechanism of integration is as of yet and to 
determine when these psychological cues turn into the neurological and molecular 
cues is something that would be beneficial. Genetic susceptibility provides an 
explanation for why people integrate the same environmental or physiological cue 
differently. The cost of food is another example of environmental cues that influence 
food intake behavior and behavioral choices. Lowering the costs of healthy foods at a 
grocery store and increasing the costs of unhealthy food does result in people 
choosing to eat more healthy (personal communication, Allan Geliebter). The taste, 
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texture and palatability of the food consumed are also properties that influence food 
consumption behavior. Even more, these properties often lead to activation of the 
dopamine or opioid pathway, which is one way behaviors are repeated and reinforced. 
These are just the tip of the iceberg for examples integrating factors that influence our 
psychology to subsequently influence our physiology, or vice versa. 
Rationale 
I am particularly interested in investigating regulation of Brain-Derived 
Neurotrophic Factor (BDNF) since it has been implicated in the etiology of human 
eating disorders, specifically obesity and anorexia31,33,37,63.  Obesity has also been 
associated with endocrine abnormalities. One example being suppressed levels of 
serum triiodothyronine (T3) in obese Zucker rats relative to the lean rats82. Given this, 
I am are proposing to use a selectively bred Fat line of animal having 255% more 
adipose tissue overall relative to a Lean line. The Fat line also has  decreased levels of 
T3 relative to a Lean line during the fed state and during development83. This is a 
useful model for identifying evolutionarily conserved processes regulating body 
composition due to alterations in the hypothalamic-pituitary thyroid (HPT) axis. 
We have obtained access to Fat and Lean lines of chicken selectively bred for 
21 generations based on adiposity or leanness.  Selective breeding allowed for 
segregation of alleles that regulate expression of these phenotypes.  More 
importantly, the contribution provided by our model of obesity stems from the fact 
that the adipose state in these lines develops independently of environmental 
influences (i.e. a high fat or high calorie diet), suggesting that development of 
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adiposity is based on genotype differences alone.  This is an extremely important 
dissociation because it is often experimentally difficult to separate out physiological 
alterations arising from increased adipose mass without having simultaneous 
alterations in food intake. Therefore, we believe we have a powerful model to better 
elucidate genetic interactions related to adiposity. With this model, we are proposing 
to use gene expression to functionally map the circuitry in the hypothalamus related 
to either a high or low adipose state, and with this we would like to elucidate and 
validate hypothalamic gene expression that influences development of either an obese 
or lean phenotype, specifically focusing on BDNF interactions with the 
hypothalamic-pituitary thyroid (HPT) axis. My overall hypothesis is that BDNF in the 
hypothalamus regulates expression of the obese or lean phenotype by interacting with 
the HPT axis (i.e. thyrotropin releasing hormone, TRH) as well as modulating 
expression of other genes known to regulate food intake, metabolic rate and body 
weight via signals that arise from Tyrosine Receptor Kinase B (TrkB) activation, the 
main mediator of BDNF signaling. My specific objectives were to complete the 
following: 1) Utilize microarray technology to identify genes and expression patterns 
during the divergence of adiposity, without simultaneous alterations in food intake.  
2) Determine which anorexigenic and orexigenic genes are altered during the 
divergence of adiposity independent of food intake alterations. 3) In primary 
hypothalamic neuronal cultures, characterize changes in mRNA levels for BDNF, 
TrkB, and TRH in response to Triiodothyronine (T3) or BDNF treatment.  4) 
Determine effects of hyperthyroidism and hypothyroidism in vivo on hypothalamic 
expression of BDNF, TrkB, TRH, and candidate genes previously shown to be 
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differentially expressed in the Fat and Lean lines, and to determine how 
glucocorticoids modulate expression of anorexigenic and orexigenic neuropeptides in 
the brain alone or in the presence of T3. 
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Chapter 2: Transcriptional profiling of hypothalamic gene 
expression during the development of adiposity in 
genetically selected fat and lean animals 
Abstract 
The hypothalamus controls many physiologic processes that can lead to 
excess adiposity, including metabolic rate, nutrient partitioning, and food intake. To 
elucidate genetic interactions within the hypothalamus that may control development 
of excess body fat, we characterized global gene expression patterns in the 
hypothalamus before and after divergence of visceral fat in Fat or Lean genetic lines 
of chickens selectively bred for high or low percent body fat. These animal lines were 
chosen because adiposity diverges between the two lines in the absence of 
environmental influences such as differences in food intake. Gene expression patterns 
during the development of adiposity were investigated using cDNA microarrays 
representing about half the genome. GeneCluster and GeneOntology were then used 
to identify biological trends and generate hypotheses associated with divergence of 
adiposity between the two lines. A model derived from the data suggests that Tumor 
necrosis factor α (TNFα) signaling may interact with other genes known to modulate 
body fat composition. Additionally, three genes involved in glycolysis were shown to 
be expressed at lower levels in the Fat line prior to the divergence of adiposity.  These 
data support the hypothesis that genotype may lead to the development of an “obese” 
phenotype through transcriptional or metabolic processes within the hypothalamus. 
Further validation of our findings will allow for identification of how these novel 





In humans and other animals, heritability and genetic susceptibility are factors 
that contribute to differences in body composition and development of an obese 
phenotype 9. The hypothalamus maintains energy homeostasis by exerting significant 
control over food intake and metabolic rate 4,5.  Previously, it has been difficult to 
dissociate genes that regulate the development of adiposity from genes that also 
regulate food intake, because these alterations often occur simultaneously. However, 
Fat and Lean lines of chicken selectively bred to be fat or lean develop adiposity 
without having simultaneous alterations in food intake 19,84,85.  These divergently 
selected animal lines provide a novel model to dissociate and identify genes that 
contribute to genetically based alteration in visceral adiposity and those that induce 
development of the fat or lean phenotypes. In this study, global gene expression 
patterns within the hypothalamus of the Fat and Lean line animals were determined 
using cDNA microarrays before and after divergence in levels of body fat between 
the lines.  The gene expression data were then clustered using self-organizing maps 
(SOMs) to identify: 1) biologically relevant patterns in the data set, 2) phenotypic 
marker genes distinguishing fat and lean animals, and 3) neighborhood marker genes 
centered around specific genes of interest that have been identified in transgenic or 
knockout mice to contribute to the obese or lean phenotype.  A novel hypothesis for 
potential interactions among genes regulating the susceptibility to obesity was then 
developed.   
Currently there are more than 600 genes identified to be associated with 
obesity, and new genes are emerging each day 16.  Here we utilize a genomic screen 
to identify novel candidate genes and biological pathways. Insight into mechanisms 
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regulating obesity can be improved by 1) dissociating the mechanisms that regulate 
obesity from those that regulate alterations in food intake, 2) identifying multiple 
factors simultaneously present in the genetic background that contribute to the 
development of obesity and 3) including a sampling time when no differences in 
adiposity are present, thus providing a baseline to compare physiological alterations 
before and after the onset of excessive adiposity.  The present study has included all 
of these features in its design. In order to provide insight into the dynamics of 
biological processes and pathways associated with the divergence of adiposity, we 
performed an analysis using well defined biological processes based on Gene 
Ontology (GO) categories and cluster analysis in order to develop two novel 
hypotheses suggesting that genes regulating TNFα signaling also interact with other 
genes known to modulate body composition and genes known to regulate glycolysis 
may contribute within the hypothalamus to regulate adiposity. 
 
Materials and Methods 
Animals and tissue preparation.  
Genetically bred fat and lean chicken lines developed at institut scientifique 
de recherche agronomique (INRA, station de recherches avicoles, Nouzilly, France) 
were used in this study (Leclercq et al., 1980). These chickens underwent genetic 
selection for about 21 generations by selectively breeding those animals exhibiting 
the greatest and lowest amount of abdominal fat at similar body weight at 9 weeks of 
age. Males were kept and reared in floor pens (4.4 x 3.9 meters). Fat (n=16) and Lean 
(n=16) chickens were reared together in the same pen to eliminate environmental 
 25 
 
differences. They were given ad libitum access to food and water throughout the 
study using conventional starter (0-3 weeks) and grower (3-11 weeks) pellet diets. 
The light/dark cycle was: 24 hr of light for the first two days post-hatch and then 14 
hr of light and 10 hr of dark thereafter.  
Animals were sacrificed at 1, 3, 5 and 7 weeks of age at INRA, with the 
hypothalamus being immediately dissected and snap frozen in liquid nitrogen (n=4 
for each age and group) and stored at –80 oC until further processing. Visceral fat, 
which is the predominating fat source in the chicken86,87, was dissected out of the 
abdominal region using a scapel. All procedures were handled in accordance with the 
Institutional Animal Care and Use Committees at INRA, the University of Delaware 
and the University of Maryland. 
Primer design and validation.  
All primers were designed using Primer Express (v 2.0, Applied Biosystems) 
and designed using a homologous region of chicken cDNAs when aligned with the 
same gene sequence for the mouse.  Primers were 18-30 nucleotides in length with a 
melting temperature between 58-64 ºC or 69-72 ºC.  Primer sequences are provided in 
Table 1. PCR products were between 100 and 150 base pairs. 
RNA isolation, cDNA preparation and quantitative PCR (qPCR).  
Individual tissue samples were homogenized and total RNA extracted with 
Rneasy Midi kits (Qiagen, Valencia, CA) according to the manufacturer’s protocol. 
Extracted RNA was quantified using UV absorbance (260/280) and integrity verified 
using a Bioanalyzer (Agilent Technologies, Palo Alto, CA). One µg RNA was used to 




GENE Sense primer Antisense primer 
Cyto b 5’TTCACATCGGACGAGGCCTAT3’ 5’CACAAAGGCGGTGGCTATGA3’ 
EF1α 5’GTGTGTGGAGAGCTTCTCCCAGTAC3’ 5’CGCTCTTCTTCTCCACGTTCTTG3’ 
ND 5’GCACTGCTGGAATTTGCTGAA3’ 5’GCCCAAGAAGCTGAAGGTCTT3’ 
Phosg 5’CACCCCTTCTTCAGCACCAT3’ 5’ATGGTGTCCTTCAGGCTCTCA3’ 
SPOCK2 5’GAAGAGCGAAGCAGCACAGT3’ 5’CCGAAGGAGAAGTTCTCGAAG3’ 
SNAP-α 5’AAGCCCACGAGGAGCAGAAC3’ 5’GCGAAGCAACATGGTTGTGA3’ 











GHRHR 5’CCTTGGCATTCGGCTTTATTTAG3’ 5’TCAGGAAACAGTAGAGGAGTGCTACA3’ 
ADAM12 5’TCAGATGAAATGAAGCAGTCA3’ 5’GTGCTCTTCCCAACTGCAAGA3’ 
GAPDH 5’AAGGAGTGAGCCAAGCACACA3’ 5’TCACTGCAGGATGCAGAACTG3’ 
Β-actin 5’CCCAAAGCCAACAGAGAGAAG3’ 5’ACCATCACCAGAGTCCATCAC3’ 
 
Table 1. qPCR primers used for verifying expression profiles.  
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(Invitrogen, Carlsbad, CA) and an oligo(dT) primer. Blank cDNA was made as a 
negative control to measure genomic DNA contamination in total RNA samples as 
described, but with no reverse transcriptase added. mRNA levels were quantified 
using 2µl of diluted cDNA (1:200) in a 20µl qPCR reaction using Sybr green realtime 
quantitative PCR master mix [2X PCR buffer containing 100 mM KCl, 20 mM Tris-
HCl (pH 9.0), 0.2% triton-X 100, 3.8 mM MgCl2, 0.12 U/µl Taq Polymerase, 400 nM 
dNTPs, 40 nM fluorescein (Invitrogen), and SYBR Green I Nucleic Acid Gel Stain 
(Invitrogen) diluted 1:10,000] and analyzed with the iCycler iQ Real-Time PCR 
Detection System (Bio-Rad, Hercules, CA) .  In all cases, a three-step PCR cycle was 
used: initial denaturation at 95 C for 3 min followed by 40 cycles of 94 oC for 45 sec, 
60 oC for 45 sec and 72 oC for 45 sec followed by a melt curve analysis to verify that 
one product was amplified.  
Microarray processing and data analysis.  
RNA samples were analyzed with cDNA microarrays, representing more than 
half the genome (14,053 genes), using a reference design. The microarrays used were 
the Del-Mar 14K Chicken Integrated Systems microarray, and a description of these 
arrays along with the annotations for each cDNA available in the Gene Expression 
Omnibus (GPL 1731). Aliquots of all RNA samples were pooled for use as an 
internal reference, with experimental samples (25 µg) labeled with Cy3 and the 
pooled reference RNA (25 µg) labeled with Cy5 during first strand cDNA synthesis. 
Microarrays were run for four ages for either the Fat or Lean line (Fat line: 4 ages, 
n=4 samples/age, Lean line: 4 ages, n=4 samples/age). The University of Maryland 
Biotechnology Institute’s Microarray Core Facility labeled the cDNA samples with 
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either Cy3 or Cy5, hybridized the microarrays, and scanned the images for processing 
(http://www.umbi.umd.edu/~cbr/macore/macorestart.htm, Rockville, MD). 
Data were analyzed using TM4 microarray suite from The Institute for 
Genome Research (TIGR).  Images were processed using Spotfinder, and data were 
Lowess normalized without background correction and regularized for standard 
deviation using Midas. Background expression was determined from 8 spots of 
salmon testes DNA and the mean pixel intensity for the spots calculated. The spots 
having a mean pixel intensity less than background were deleted from the analysis. 
Out of 19,200 total spots on the microarray, 14,063 genes comprising about half the 
chicken genome were represented. Data points were deleted if more than half the data 
points were not present. From this, statistics were ran on 6,041 data points and 
significant differences in gene expression were identified for 790 genes (P<.05) by 
ANOVA using the Statistical Analysis System (Statistical Analysis System, v.8.02, 
SAS Institute, Cary, NC). The 790 significant genes were preprocessed in 
Genecluster version 2.1.7 (Broad Institute, Cambridge, MA) by normalizing 
expression levels to have a mean=0 and variance=1 and then clustered by SOMs to 
identify 18 different patterns of expression between the two genetic lines (3x6 
arrangement). qPCR was performed to confirm the microarray results and included all 
samples used for Cy3 labeling and the pooled RNA used for the Cy5-labeled 
reference. All data for both qPCR and microarray are presented with the mean data 
point equal to one, in order to place both data sets on the same scale.  
Statistical analysis and graphical display of data.  
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PCR products were verified for the appropriate size with dissociation curve 
analysis and gel electrophoresis.  The qPCR output data provided a Ct value for the 
threshold cycle.  The Ct value represents the threshold cycle, which is achieved when 
the amount of amplified product reaches a fixed threshold for fluorescence due to 
binding of SYBR green to the double-stranded PCR product.  Data were first 
transformed to a ∆Ct value by subtracting the sample Ct value from the sample with 
the highest expression level in order to control for amplification efficiency (GeNorm 
v3.4) 88. The ∆∆Ct value was generated using geNorm software and methods 88.  
Briefly, the data were first transformed to a ∆Ct value by subtracting the sample Ct 
value from the sample with the highest expression level in order to control for 
amplification efficiency. The ∆∆Ct value was then calculated by normalizing gene 
expression to two housekeeping genes, β-actin and GAPDH.  
All comparisons of values for qPCR were made using a two-way ANOVA 
(line by week) with a Pdiff post-hoc analysis used to identify individual differences 
between the groups at different ages (Statistical Analysis System, v.8.02, SAS 
Institute, Cary, NC). Values reported are means + SEM, and for all statistical tests P< 
0.05 was required for significance. Graphpad was used to construct all graphs 
(Graphpad Prism Version 4.0, Graphpad Software, Inc.).  
Results 
Exploratory data analysis for hypothalamic gene expression: general phenotype 
features 
We have identified 561 genes differentially expressed by line and 442 genes 
significant for line-by-age interactions using a two-way ANOVA. Additionally, 77 
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genes were differentially expressed between lines having at least 160% expression 
difference during the development of adiposity. A table including all means, SEM, 
and P-values and all of the normalized and non-normalized microarray results are 
available in the Gene Expression Omnibus (GSM231561-231590).  A subset of genes 
have been shown to correlate with either the Fat or Lean phenotype, suggesting that 
21 generations of selective breeding resulted in segregation of alleles for genes 
expressed in the hypothalamus that correlate with the Fat and Lean phenotypes.  
Genes most closely correlated with expression specific to either the Fat or Lean line 
are shown (Fig 1a, lean line: weeks 1, 3, 5, and 7; and 1b, fat line: weeks 1, 3, 5 and 
7; 40 each).  Self-Organizing Maps (SOMs) clustering allows identification of 
fundamental patterns of gene expression for a phenotype of interest 89, and this 
analysis was applied to the genes found to be expressed at significantly different 
levels between the lines (Fig. 2). Genes differentially expressed between the Fat and 
Lean lines were organized in this manner in order to identify biologically relevant 
clusters to develop novel hypotheses for the divergence of either the fat or lean 
phenotype. Each cluster represents the mean of all genes within the cluster, and 
expression levels were normalized to have a mean = 0 and SD = to 1 across time 
points 89. The data are presented in a 3x6 SOMs.  We verified the accuracy of the 
expression patterns for eight clusters, 13 genes, plus GAPDH and β-actin, using 















Figure 1. Hypothalamic expression patterns that correlate with either the Fat or 
Lean phenotype. a) 40 genes most closely correlated to be upregulated in the Lean 
line relative to the Fat line before (week 1), during (week 2 and 5) and after the 
development of adiposity (week 7).  b) 40 genes most closely correlated to be 
upregulated in the Fat relative to Lean line over weeks 1-7, before, during and after 
the divergence of adiposity.  All genes are differentially expressed between lines 
(P<.05) and ranking is calculated based on the difference of the means for each line 
scaled by the sum of the standard deviations (x1-x2)/(x12+x22)1/2.  Genes in red 










Fig 2. Self-organizing maps (SOMs) analysis demonstrating biologically relevant 
clusters and expression patterns between the fat and lean lines.  3x6 SOM with 18 
clusters (cluster0-cluster17) using 791 genes, with 561 significant by lines and 442 
significant for the line-by-age interaction (P<.05). The number of genes included in 












































GENE Spot Cluster 
Cytochrome b (Cyto b) 17687 5 
Elongation factor 1 α (EF1α)  16106 17 
No description (ND) 17744 3 
Phoshpoglycerate mutase (Phosg mut) 6482 17 
Sparc/osteonectin (SPOCK2) 6854 10 
Soluble NSF-attachment protein (SNAP α) 16210 16 
5-tryptophan hydroxylase (5-HTP) 7185 6 
Phosphoglucose isomerase 73 16 
Neural Enolase 13011 17 
CCAAT/enhancer-binding protein (CEBP) 19069 12 
Induced by TNF alpha (TNF AP)  10372 14 
Growth hormone releasing hormone receptor (GHRHR) 11448 6 
Metalloprotease 1  13505 6 
 
Table 2. Verification of expression profiles by qPCR was performed on the above 




















Hypothalmic gene expression profiles during the development of adiposity 
divergence. 
The hypothalamus has been shown to be an area of the brain that modulates body 
weight and adiposity.  We analyzed gene expression for Fat and Lean lines at 1, 3, 5 
and 7 of age to measure differences in gene expression correlating with the 
development of the phenotypes. There were no differences in adiposity at week 1 of 
age, providing a baseline to compare physiological alterations before and after the 
onset of excessive adiposity. Differences in adiposity developed by week 3 in the Fat 
relative to Lean line. Thus, we sought to investigate which genes were differentially 
expressed prior to and/or after the divergence of adiposity (Table 3a and b). Criteria 
for an upregulated or down regulated gene were as follows: 1) gene expression must 
be significantly different by line or line-by-age as identified by the microarray 
(P<.05, 790 genes total), 2) Fat line > Lean line was termed upregulated and Fat line 
< Lean line was termed downregulated, and 3) at the age of interest there must be no 
overlapping error bars between the data points, as presented in the SOMs cluster data 
(Fig. 2). Nine clusters contained gene expression patterns being upregulated at week 1 
in the Fat line, prior to any divergence in adiposity between the Fat and Lean lines 
(Fig. 2, clusters: 0, 1, 2, 6, 7, 8, 12, 13, 14, n=427 genes), eight clusters contained 
gene expression patterns being downregulated in the Fat line at the same age (Fig. 2, 
clusters: 4, 5, 9, 10, 11, 15, 16, 17, n=325 genes) and one cluster had no difference 














Fig 3. qPCR verification of SOMs clusters. QPCR results demonstrate a 
correspondence with the reported microarray data. Microarray data are shown on the 
left and qPCR data are presented on the right of each graph. Microarray data have 
been converted from a log value, compressing the data points to be centered around 
the value of 1. Fat line is represented with the closed bar and Lean line with the open 
bar. Values reported are means ± SEM, P<0.05. * denotes differential expression 



































            
Table 3a. The total number of upregulated and downregulated genes in the Fat    
          relative to Lean line at week 1 or week 3.          
                                   upregulated        downregulated 
                     Wk 1                Wk 3             Wk 1                Wk 3 
             
Fat vs Lean         427 (54%)         321 (40%)           325 (41%)         144 (18%) 
            
Transcription –    31 (7.6%)           22 (6.8%)             19 (5.8%)          12 (8.3%) 
DNA dependent            
            
signal transduction   29 (6.8%)           18 (5.6%)             15 (4.6%)            6 (4.1%) 
            
transcription      24 (5.6%)           17 (5.3%)            15 (4.6%)          11 (7.6%)                                
            
protein biosynthesis   12 (2.8%)           12 (3.7%)             17 (5.2%)            2 (1.4%) 
            
transport               15 (3.5%)             9 (2.8%)             15 (4.6%)          10 (6.9%) 
            
biological process    17 (4.0%)             4 (1.2%)             11 (3.4%)            9 (6.2%) 
unknown 
            
metabolism         9 (2.1%)             4 (1.2%)             10 (3.1%)            2 (1.4%) 
            
carbohydrate         4 (.01%)             5 (.02%)               4 (.01%)            1 (.01%) 
 metabolism 
            
lipid metabolism    5 (1.2%)             4 (1.2%)               4 (1.2%)            2 (1.4%) 
            
glycolysis     0 (0.0%)             4 (1.2%)               5 (1.5%)            0 (0.0%) 
            
*Gene numbers represent genes obtained using a p-value < .05, 790 genes total. 
Biological processes on the left obtained from GO analysis. 
 
            
Table 3b. The total number of upregulated and downregulated genes in the Fat 
             relative to Lean line at week 5 or week 7.      
                            upregulated                   downregulated 
                     Wk 5                Wk 7             Wk 5                Wk 7 
            
Fat vs Lean         372 (47%)         160 (20%)           266 (34%)         223 (28%) 
            
Transcription –    23 (6.2%)           11 (6.8%)             17 (5.4%)          15 (6.7%) 
DNA dependent            
            
signal transduction   24 (6.4%)            7 (4.4%)             10 (3.8%)          11 (4.9%) 
            
protein biosynthesis     8 (2.1%)            3 (1.9%)             11 (4.1%)          12 (5.4%) 
            
transport               14 (3.8%)           10 (6.2%)             13 (4.9%)            9 (4.0%) 
            
biological process    12 (3.2%)             9 (5.6%)             10 (3.8%)            9 (4.0%) 
     unknown 
            
metabolism          5 (1.3%)             5 (3.1%)             10 (3.8%)            4 ( 1.8%) 
            
carbohydrate           6 (1.6%)             4 (2.5%)               3 (1.1%)            3 (1.3%) 
  metabolism   
            
lipid metabolism     5 (1.3%)             4 (2.5%)               3 (1.1%)            2 (0.1%) 
            
glycolysis      2 (0.01%)           0 (0.0%)               3 (1.1%)            4 (1.8%) 
            
*Gene numbers represent genes obtained using a p-value < .05, 790 genes total. 
Biological processes on the left obtained from GO analysis. 
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the two lines, week 3, fewer clusters exhibited upregulated expression patterns (Fig. 
2, five clusters: 12, 13, 14, 16, 17, n=321 genes) and even fewer exhibited 
downregulated expression patters in the Fat relative to Lean line (Fig. 2, four clusters: 
1, 2, 3, 10, n=144 genes) (Table 3a). Many more genes were upregulated or 
downregulated in the Fat relative to Lean line at week 1 of age relative to week 3 of 
age. This is likely attributable to developmental processes or neural circuitry being 
established during this age. This also suggests that the development/establishment of 
these neural processes could contribute to the differential gene expression observed 
and, more importantly, to the differential phenotype observed between the two lines.  
Given this, we identified groups of functionally related genes to better determine 
what processes could modulate this effect.   
GO processes at the gene level that are specific for either the fat or lean phenotype 
In order to better understand the functionality of the expression patterns 
related to the development of adiposity, we utilized the Gene Ontology system (GO). 
The GO system allows for the following three main classes of processes to be 
distinguished between the Fat and Lean lines: biological processes, molecular 
functions and cellular processes. We chose to focus our analysis on biological 
processes, since we would like to identify how selective breeding altered genetic 
expression resulting in changes in biological processes that lead to the fat or lean 
phenotypes.  
Out of all significant genes (P<.05) and genes with the greatest fold difference 
of expression between the two lines (82 genes, 160% or greater fold difference), 
regulation of transcription and signal transduction were processes that encompassed 
 42 
 
the largest number of genes differentially expressed between the two lines, but 
glycolysis was the process most strikingly different during the development of 
adiposity (Fig. 4). Glycolytic genes comprised a very small number of all significant 
genes (2.1%), but encompassed a larger percentage of genes with the greatest fold 
difference (9.1%) (Fig. 4). This suggests that genes known to regulate glycolysis 
within the hypothalamus may have played a large role in driving the difference 
between the two phenotypes.  
At week 1 of age, there were 5 glycolytic genes downregulated and no genes 
upregulated in the Fat relative to Lean line (Table 4).  All of these genes are involved 
in catalyzing a different step of glycolysis, suggesting that prior to the divergence of 
adiposity the Fat line may have had a lower level of glucose metabolism in the 
hypothalamus relative to the lean line, which corresponds with the overall decreased 
level of plasma glucose in the Fat line (Table 5)90. After adiposity differences began 
to diverge between the lines at week 3 of age this trend reversed. The same genes that 
were downregulated at week 1 were upregulated at week 3 in the Fat relative to Lean 
line (Table 3a), suggesting that differences were present prior to the divergence in 
adiposity and reversed once adiposity differences began to emerge between the two 
lines. Aldolase C was the only gene involved in glycolysis not different at this point 
in time. This pattern continued at week 5 of age with 2 genes regulating the first two 
steps in glycolysis still being upregulated (Phosphoglucose isomerase and 






Figure 4. Gene Ontology (GO) analysis for differentially expressed genes in the 
hypothalamus. Genes on the left exhibit GO distribution for only the genes with 
150% or greater fold difference between the Fat and Lean lines and genes on the right 




             
Table 4. Genes involved in glycolysis 
            
 
Spot     Microarray Gene           Function            Glycolysis step # 
     (out of 10)  
            
 
4930 Hexokinase 1  converts glucose to glucose-6-phosphate                     1  
73 Phosphoglucose   interconversion of glucose-6-phosphate and          2 
      isomerase       fructose-6-phosphate 
3836 Aldolase C  cleaves fructose-1-phosphate to dihydroxyacetone           4 
          phosphate and D-glyceraldehyde 
6482 Phosphoglycerate mutase converts 3-phosphoglycerate to 2-phosphoglycerate       8  


















Table 5. Phenotypic data for Fat and Lean lines of chicken. 
Age (wk)   1                    3                    5                     7                 9                    11  
                       
Body weight (g) 
Fat      115 ±  4.0     544 ±  21     1297 ±  37*   1983 ±  36   2693 ±  91     3222 ±  154 
Lean   123 ±  3.0     551 ±  16     1204 ±  21*   1964 ±  40   2787 ±  53     3281 ±  302 
            
Abdominal fat (g)                   
Fat         0.5 ±  0.1     13 ±  1.0*      38 ±  2.0*      88 ±  3.0*  124 ±  8.0*    150 ±  20* 
Lean      0.4 ±  0.1       5 ±  0.5*      15 ±  2.0*      31 ±  2.0*    54 ±  8.0*      59 ±  10* 
            
Abdominal Fat:body weight (%)                      
Fat         0.4 ±  0.1    2.3 ±  0.1*      2.9 ±  0.2*     4.4 ±  0.2*   4.6 ±  0.3*    4.6 ±  0.5* 
Lean      0.3 ±  0.1    1.0 ±  0.1*      1.2 ±  0.1*     1.6 ±  0.1*   1.9 ±  0.3*    1.8 ±  0.3* 
            
Plasma Insulin (ng/mL)           
Fat         1.3 ±  0.3    1.3 ±  0.3        1.7 ±  0.3       1.6 ±  0.2     1.5 ±  0.4      1.4 ±  0.2 
Lean      0.9 ±  0.2    1.3 ±  0.2        1.7 ±  0.2       1.2 ±  0.2     1.2 ±  0.2      1.2 ±  0.1 
            
Plasma Glucose (mg/100mL)  
Fat        232 ±  6.0   237 ±  3.0*     225 ±  6.0*     41 ±  8.0     231 ±  5.0     222 ±  7.0 
Lean     246 ±  5.0   254 ±  4.0*     245 ±  6.0*   249 ±  4.0     233 ±  4.0     232 ±  6.0 
            
Mean ± SEM, n=8, *p<0.05 in a one-way ANOVA comparing Fat and Lean lines of 













downregulated (Aldolase C, Phoshpoglycerate mutase and Neural Enolase). By week 
7 of age, when the divergence in adiposity had started to stabilize between the two 
lines (Table 5), the expression pattern of most genes regulating glycolysis were 
similar to the patterns observed at week 1 of age, with four of the genes being 
downregulated and no change between the lines for Aldolase C (Table 3b). To verify 
expression patterns for some of the glycolytic genes, we ran qPCR on the following 
three genes: Phosphoglucose isomerase, Phoshpoglycerate mutase and Neural 
Enolase (Fig. 5). No other biological processes demonstrated such pivotal and distinct 
changes in expression during the development of adiposity. These results suggest that 
genes regulating glycolysis could promote divergence of the fat or lean phenotype.   
Next, we chose to annotate SOMs cluster 17 with GO processes in order to 
determine which biological processes were upregulated and downregulated during 
adiposity development (Table 6). We chose cluster 17 because there were two genes 
regulating steps 8 and 9 of glycolysis in this cluster, Neural enoloase and 
Phosphoglycerate mutase. Thus, we wanted to further identify other biological 
processes downregulated that might be biologically relevant to the glycolytic 
pathway. Of the 69 genes in the cluster all genes were linked to a GO term. Presented 
in table 6 are biological processes having at least 2 genes in a category, unless it was 
involved with metabolism. Interestingly, the genes in this cluster were mainly 






            
Table 6 Gene Ontology (GO) analysis for cluster 17     
Biological Process          # of Genes      Gene Name  
                             
Protein Biosynthesis              5           Seryl-tRNA synthetase 
                                                 Eukaryotic translation EF1α 
Ribosomal protein L17 
Ribosomal protein L35A 
Ribosomal protein L26 
            
Regulation of             6          non-POU domain containing 
transcription DNA   Calreticulin 
dependent    No Hits Found 
multiple endocrine neoplasia 1 
PQBP-1b/c 
TSC-22 
            
G-protein receptor             3           G protein-coupled receptor 123 
Signaling    Amyloid-like protein 2 precursor 
     tubulin beta 3  
            
Proteolysis             3          ADAM 12 
     F-box only protein 3 
     No Hits Found 
            
Protein Polymerization          3           tubulin alpha 1 
     tubulin beta 3 
     tubulin beta 5 
            
Protein Folding            2           Calreticulin 
Calnexin 
            
Glycolysis             2           Phosphoglycerate mutase 1 
                                                 Neural enolase  
            
Carbohydrate Metabolism     1            Klotho secreted isoform     
            
Metabolism                        3           Phosphoglycerate mutase 1 
     Phospholipid-transporting ATPase 
     Retinol dehydrogenase 11 
            
Intracellular protein               3           Golgi SNAP receptor complex 
transport    Soluble NSF-attchment protein alpha 
     adaptor-related protein complex 2 
            
Cell adhesion                         3            ADAM 12 
     Beta-amyloid precursor protein 
     Glucose Regulated Protein, 95-KD (Grp94)      
            
Microtubule-based                3            tubulin alpha 1 
movement    tubulin beta 3 
     tubulin beta 5 
            
Bold denotes qPCR verification for microarray data. Italic denotes a homologues  






Figure 5. Expression pattern verification for genes involved in glycolysis, Table 
3c and Table 6. Data expression patterns are similar for both the microarray (left) 
and qPCR (right).  Fat line is represented with the closed bar and Lean line with the 
open bar. The log scale microarray data has been converted, which compresses the 
data points around the value of 1. Values reported are means ± SEM, P<.05. * 




the gene profiles observed in the cluster, we performed qPCR for five of the genes  
(Fig. 3, 5, and 7), with two of these being involved in glycolysis, Neural Enolase and  
Phoshpoglycerate mutase (Table 4 and Fig. 5), as well as one gene involved with 
intracellular transport and one involved with protein biosynthesis (Fig. 3).  In most 
cases, gene expression profiles determined from the microarray analysis were 
confirmed by qPCR. 
Biological processes and adiposity divergence. 
More than 600 genes have been associated with body weight and adiposity in 
other species, with 166 of these genes being linked directly to body composition or 
metabolism by knockout and transgenic mouse technologies 16. To assess their 
potential role within the hypothalamus leading to the fat and lean phenotypes, we 
compared these 166 genes with the 790 genes identified by the microarray analysis. 
From this we identified 24 genes that were homologous or directly related to the 
biological signaling of the gene. We then selected a small number of these genes to 
pursue further. The selection for these genes was based on having high similarity to a 
gene family known to modulate body composition with the gene itself not having yet 
been identified to be linked to body composition (Table 7). 5 out of the 6 genes had 
predicted gene expression differences in the Fat and Lean line, all except 
Metalloprotease 1. From this, we verified expression levels for three genes with 
qPCR, CEBPζ, a gene induced by TNF α (TNF AP) and Metalloprotease 1 (Fig.6). 
Since the genes may be functioning in a similar manner as the knockout or transgenic 
mouse, mechanisms created by allelic segregation, we then ran a marker specific 
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Table 7. Genes identified in the microarray and their homologues in knockout or 
transgenic mice. 
            
Spot     Microarray Gene         Knockout gene/             Microarray 
                           Transgenic                  Phenotype   Expression 
                
10372 TNFα induced protein          TNFα overexpression    obese      Fat Line  ↑ 
16446 Zinc Finger Protein 36          ZFP36 -/-                        obese      Fat Line  ↓ 
13505 Metalloprotease 1           ADAMS TS -/-               lean       Lean line ↓ 
17139 ADAM12 precursor           ADAMS TS -/-               lean       Lean line ↑                      
5763 Isocitrate Dehydrogenase      IDPc overexpression      obese      Fat Line  ↑ 








Figure 6. Expression pattern verification for genes identified by comparison of 
significant genes. Increased expression patterns for the Fat line relative to Lean at 
week 1 of age are increased for all genes presented in our hypothetical model. These 
trends confirm predictions in Table 5.  Two of these genes have been identified in 
published lists identifying knockout or transgenic mice with alterations in body 
composition, CEBP and TNF AP, and two genes were identified using the KNN 
algorithm, GHRH receptor and Metalloprotease 1 (Fig 7a). Fat line is represented 
with the closed bar and Lean line with the open bar. The log scale microarray data has 
been converted, which compresses the data points around the value of 1. Values 
reported are means ± SEM, P<.05. * denotes differential expression between the lines 











analysis (KNN algorithm) using these genes (Table 7) to generate a hypothetical 
model. The marker specific analysis allows identification for genes that may be 
biologically relevant with one another, based on similarity of expression profile. 
Of the candidate genes listed in Tables 4 and 7, one gene at a time was used as 
a marker for analyzing the microarray data, as well as to determine the following: 1) 
genes which are most closely correlated with one another, 2) potential candidate 
genes that may be an upstream regulator or downstream target of gene expression and 
3) genes that are candidates for interacting with genes involved with glycolysis or 
genes previously identified through the transgenic/knockout comparison. We chose to 
run this analysis on genes already confirmed to be involved with regulating the 
development of adiposity or body weight in other species (Tables 8-12) or for genes 
involved with glycolysis (Tables 13-17), and our results are rather intriguing.  From 
this data we propose two hypothetical models based on the gene expression patterns 
(Fig. 7a and b).  
From the data we show that genes involved in TNFα signaling are linked to 
microarray expression patterns (Fig. 7a). For example, TNF receptor associated factor 
1 (TRAF-1) is potentially related biologically to many genes already identified to 
modulate body composition, such as the following: the rate limiting factor for 
serotonin synthesis 5-tryptophan hydroxylase (5-HTP), growth hormone releasing 
hormone receptor (GHRHR), sweet taste receptor T1R1, and metalloprotease 1 
















Figure 7. Potential genetic interactions identified by specific gene marker 
analysis. a) Genes known to modulate body composition (Table 3) are identified as 
being linked to the TNFα singalling processes. b) Genes known to modulate 
glycolysis are linked to Klotho, Dihydropyrimidase protein-2 (DRP2), and ADAM 
12. These are key candidate genes known to modulate body composition that may 
interact upstream or downstream of one another. Differential gene expression occurs 
primarily at week 1 of age, as identified by qPCR.  The dashed lines indicate that the 




Table 8 Marker selection analysis for TNF receptor associated factor 1  
Gene Name                      Spot       Score  
                          
tumor necrosis factor type 1  15016  0 
MAP kinase phosphatase-1  14632  0 
preprocarboxypeptidase A   2215  0.01 
protein tyrosine phosphatase  1679  0.01 
No Hits Found_49   5980  0.02 
immunoglobulin-like receptor   5532  0.02 
ezrin     17732  0.02 
UDP-glucuronosyltransferase 1A9  9610  0.02 
similar to Heat shock protein HSP 90-alpha  5677  0.02 
Sk-tropomodulin    13748  0.02 
Unknown protein_4   2775  0.02 
Tryptophan 5-monooxygenase  7185  0.03 
Cytochrome P450    17362  0.03 
KIAA0232 protein   8499  0.03 
chromosome 20 open reading frame 149  13481  0.03 
No Hits Found_99   4689  0.03 
ankyrin repeat    5336  0.03 
acid alpha glucosidase   12981  0.03 
No Hits Found_85   15679  0.03 
Peroxisomal coenzyme A diphosphatase 4869  0.03 
No Hits Found_80   11711  0.04 
vacuolar protein sorting 4 homolog B 498  0.04 
Similar to LIM domains   16825  0.04 
Serum albumin precursor   13896  0.04 
similar to Np95-like ring finger protein 10599  0.04 
Acylphosphatephosphohydrolase  14313  0.04 
hypothetical protein MGC38361  13731  0.04 
No Hits Found_58   16838  0.04 
No Hits Found_88   14208  0.04 
aldo-keto reductase    2889  0.04 
mitochondrial ribosomal protein S25 2875  0.04 
Unknown protein _3   2888  0.04 
putative sweet taste receptor T1R1 17155  0.04 
No Hits Found_129   9825  0.04 
hypothetical protein_3   12224  0.04 
No Hits Found_3    10789  0.05 
LAP      12407  0.05 
No Hits Found_64   17248  0.05 
ribosome-binding protein    14626  0.05 
No Hits Found_46   16241  0.05 
cytochrome P450 (CYP27A1)  5763  0.05 
No Hits Found_29   12453  0.05 
Creatine kinase    15098  0.05 
target of Jun 3    474  0.05 
No Hits Found_6    10653  0.05 
No Hits Found_54   15755  0.05 
No Hits Found_31   12392  0.06 
GHRH receptor    11448  0.06 
Ig gamma chain    11778  0.06 
AI182287     7560  0.06 





Table 9 Marker selection analysis for metalloprotease 1    
Gene Name                     Spot       Score  
                         
Metalloprotease 1  13505  0 
MOX-2 protein   10314  0.16 
No Hits Found_24  11934  0.17 
Tnf receptor-associated factor 2 12802  0.19 
hypothetical protein _1  17246  0.24 
No Hits Found_64  17248  0.24 
proline-rich protein   15447  0.24 
RIKEN cDNA 5430432P15  16539  0.24 
c6.1a protein   3113  0.25 
Estrogen-regulated protein  18505  0.25 
No Hits Found_131  2550  0.25 
No Hits Found_98  1999  0.26 
chromosome 20 ORF 149   13481  0.26 
No Hits Found_95  15307  0.26 
meiosis-specific MutS   16256  0.26 
Ig gamma chain   11778  0.26 
interferon regulatory factor 5  16603  0.28 
FLJ00039 protein   6119  0.28 
DKFZP586A0522 protein  1980  0.28 
coronin 7   6094  0.29 
selenoprotein SelM  5038  0.29 
No Hits Found_83  6267  0.3 
No Hits Found_112  1341  0.31 
novel glycoprotease  17485  0.31 
translation termination factor 1 15127  0.31 
septin 6     13333  0.31 
No Hits Found_85  15679  0.31 
similar to RIKEN cDNA  18314  0.31 
5-aminolevulinic acid synthase 13255  0.32 
unnamed protein product _7 18984  0.32 
No Hits Found_54  15755  0.32 
Similar to LIM domains  16825  0.32 
DNA-directed DNA polymerase  16612  0.32 
No Hits Found_80  11711  0.32 
similar to CG3714-PA  11017  0.32 
No Hits Found_3   10789  0.33 
No Hits Found_105  6711  0.33 
immunoglobulin-like receptor  5532  0.33 
No Hits Found_101  9678  0.33 
unnamed protein product_13 18002  0.33 
putative sweet taste receptor T1R1 17155  0.34 
hypothetical protein MGC38361 13731  0.34 
fast myosin heavy chain isoform 2 12332  0.34 
heat shock protein 40  17417  0.35 
zinc finger protein 1  14057  0.35 
outer dense fiber of sperm tails 2 10349  0.35 
CREATINE KINASE  15098  0.35 
tumor necrosis factor type 1 15016  0.36 
No Hits Found_88  14208  0.36 
N-deacetylase/N-sulfotransferase  10917  0.36 





Table 10 Marker selection analysis for Isocitrate Dehydrogenase   
Gene Name                     Spot       Score  
                         
Isocitrate dehydrogenase  16230  0 
Putative protein C21orf45  346  0.03 
visinin-like 1   11435  0.04 
No Hits Found_67  14042  0.04 
unnamed protein product_9 5958  0.05 
poly(A) binding protein  1670  0.05 
eukaryotic initiation factor 5  11520  0.05 
No Hits Found_130  16172  0.05 
similar to LPS-responsive   11025  0.05 
No Hits Found_5   17423  0.05 
RIKEN cDNA 1110066L09 17279  0.05 
serine incorporator 1   9694  0.05 
ATP synthase alpha subunit_1 8133  0.06 
DEAH box isoform  2736  0.06 
No Hits Found_84  4336  0.06 
ATP synthase alpha subunit 13508  0.06 
prenyl protein protease   9139  0.06 
NEURONAL PROTEIN 3.1 4912  0.06 
HSPC288    13041  0.06 
GAPDH    14661  0.07 
deoxyhypusine synthase  16197  0.07 
similar to RALY   1194  0.07 
trypsin domain containing 1 10806  0.07 
No Hits Found_34  2861  0.07 
vesicle associated protein  5128  0.07 
agCP3452    8686  0.08 
hnRNPC related   6730  0.08 
Lipid Transfer ProteinII  12459  0.08 
unnamed protein product_1 4379  0.08 
RIKEN cDNA _1  7775  0.08 
similar to GS15    7790  0.08 
No Hits Found_25  7453  0.08 
mitochondrial ribosomal prtn S23 17989  0.09 
No Hits Found_116  14562  0.09 
No Hits Found_15  11568  0.09 
ankyrin 2   17734  0.09 
Nesprin-2   843  0.09 
pre-mRNA splicing factor_2 14844  0.09 
extensin    17131  0.09 
Alpha1,2-Mannosidase  13854  0.09 
No Hits Found_127  18905  0.1 
Rho-related    1196  0.1 
RIKEN cDNA 2610209N15  4982  0.1 
mitochondrial ribosomal prtn L17 16194  0.1 
hypothetical protein_8  5165  0.1 
hypothetical protein_7  5205  0.1 
Lipoate synthase   6863  0.1 
pre-mRNA splicing factor  9696  0.1 
No Hits Found_70  4448  0.1 
endocrine neoplasia 1   12899  0.1 





Table 11 Marker selection analysis for Induced by TNF alpha (TNF AP)   
Gene Name                      Spot        Score  
                          
induced by tumor necrosis factor alpha 10372  0 
c-src tyrosine kinase    10037  0.03 
SPT3-associated factor    2884  0.03 
similar to exocyst complex component 3 6894  0.03 
splicing factor 3a    10344  0.04 
No Hits Found_60   1724  0.04 
Ribonuclease CL2    13900  0.04 
GATA-2    5044  0.05 
LIM-domain protein CRP1  13465  0.05 
disintegrin-like and metalloprotease domain 4482  0.05 
IGF-binding protein 2   3240  0.05 
Tropomyosin 1 alpha chain  17149  0.05 
eukaryotic translation initiation factor 3, s6  628  0.05 
Similar to CGI-67 protein    14406  0.05 
FLJ22611-like protein   3250  0.05 
vesicle-associated membrane protein  16240  0.05 
No Hits Found_33   10679  0.05 
nucleotide pyrophosphatase 3  593  0.06 
type V preprocollagen alpha   4453  0.06 
Unknown protein_1   3921  0.06 
Rho GTPase activating protein 26  11565  0.06 
TROPONIN I    2751  0.06 
FLJ00315 protein   17077  0.06 
muscle specific gene   8010  0.06 
hypothetical protein _3   10193  0.06 
origin recognition complex  2327  0.06 
polymerase II polypeptide C  2825  0.07 
No Hits Found_7    4878  0.07 
glucokinase     1753  0.07 
hypothetical protein FLJ11200   15682  0.07 
heat shock protein 40   17417  0.07 
Tcf-3 co-repressor CtBP   161  0.07 
phosphatidylinositol transfer protein 9927  0.07 
RB1-inducible coiled-coil 1  7105  0.08 
Ferredoxin-NADP(+)reductase  1322  0.08 
PTEN induced putative kinase 1  15035  0.08 
NADH dehydrogenase flavoprotein 1 5452  0.08 
Collagen alpha 1    5378  0.08 
chloride channel 7   530  0.08 
Creatine kinase    15098  0.08 
Arp23      9681  0.08 
ATP synthase beta chain   1743  0.08 
coronin, actin binding protein, 2B  14087  0.09 
eukaryotic translation elongation factor 1_2 15734  0.09 
BLOCK 25    7848  0.09 
hypothetical protein   16484  0.09 
Apolipoprotein A-I   12316  0.09 
Calpactin I light chain    2210  0.09 
No Hits Found_72   1662  0.09 
ATP/GTP-binding protein   8012  0.09 





Table 12 Marker selection analysis for CEBPζ    
Gene Name                      Spot       Score  
                          
CEBPζ     19069  0 
RB1-inducible coiled-coil 1  7105  0.05 
ATP synthase beta chain   1743  0.05 
KIAA1892 protein    4417  0.05 
NADH dehydrogenase flavoprotein 1 5452  0.06 
RIKEN cDNA _4   3763  0.06 
IQ motif containing K (IQCK)  244  0.07 
heat shock protein 40   17417  0.07 
N-deacetylase/N-sulfotransferase   10917  0.07 
Unknown protein _5   357  0.07 
CREATINE KINASE   15098  0.08 
disintegrin-like and metalloprotease domain 4482  0.08 
polymerase II polypeptide C  2825  0.09 
Ferredoxin-NADP(+)reductase\  1322  0.09 
interleukin enhancer binding factor 2 9723  0.09 
Tropomyosin 1 alpha chain  17149  0.09 
Unknown protein_1   3921  0.09 
eukaryotic translation initiation factor 3, s6  628  0.1 
mitochondrial ribosomal protein S25 2875  0.1 
No Hits Found_86   4050  0.1 
chloride channel 7   530  0.1 
origin recognition complex  2327  0.1 
Unknown protein _3   2888  0.11 
phosphatidylinositol transfer protein 9927  0.11 
No Hits Found_54   15755  0.11 
induced by tumor necrosis factor alpha 10372  0.12 
No Hits Found_85   15679  0.12 
ADP-ribosylation-like factor 6   13499  0.12 
Tryptophan 5-monooxygenase  7185  0.12 
novel glycoprotease   17485  0.12 
hypothetical protein FLJ11200   15682  0.12 
importin 13    1294  0.12 
Similar to LIM domains   16825  0.13 
target of Jun 3    474  0.13 
inhibitor of growth family, member 3 13496  0.13 
immunoglobulin-like receptor   5532  0.13 
Rho GTPase activating protein 26  11565  0.13 
Cytochrome P450    17362  0.13 
hypothetical protein_4   17208  0.14 
No Hits Found_7    4878  0.14 
No Hits Found_60   1724  0.14 
coronin, actin binding protein, 2B  14087  0.14 
infertility-related sperm protein  6576  0.14 
Acylphosphatephosphohydrolase  14313  0.14 
photomedin-1    7902  0.14 
Tcf-3 co-repressor CtBP   161  0.15 
Peroxisomal coenzyme A diphosphatase 4869  0.15 
glucokinase     1753  0.15 
No Hits Found_139   4526  0.15 
leukotriene B4 12-hydroxydehydrogenase 680  0.15 





Table 13 Marker selection analysis for phosphoglucose isomerase  
Gene Name                      Spot       Score  
                          
phosphoglucose isomerase  73  0 
tetraspan 3    17122  0.01 
retinoblastoma tumor suppressor  9201  0.02 
ACTIN, CYTOPLASMIC TYPE 5  4161  0.02 
nuclear distribution gene C   17031  0.02 
endocrine neoplasia 1    12899  0.02 
ADAM 12    17139  0.02 
tubulin, beta 5     2954  0.03 
Similar to macropain   13235  0.03 
unnamed protein product    3853  0.03 
LEP100 protein     14458  0.04 
beta-amyloid precursor   3906  0.04 
ubiquitin-like 3    18010  0.04 
No Hits Found_116   14562  0.04 
eukaryotic translation elongation factor 1_1 16106  0.05 
ERO1-like    9129  0.05 
POL-like    15506  0.05 
Neural enolase (NSE)   13011  0.05 
EST H08032.1     13326  0.05 
vesicle associated protein   5128  0.05 
Similar to hypothetical protein  14095  0.05 
Dihydropyrimidinase related protein-2 12821  0.05 
tubulin, beta     9603  0.05 
KIAA0605 gene product   13929  0.05 
malignant liposarcoma    6875  0.06 
synapsin Iib    14818  0.06 
vesicular fusion protein NSF  9664  0.06 
adenosinetriphosphatase   13232  0.06 
hexokinase1     10230  0.07 
gamma-synergin    14853  0.07 
Ubiquitin thiolesterase 1   13281  0.07 
unnamed protein product _13  2687  0.07 
similar to Eferin    15094  0.07 
pre-mRNA splicing factor_1  14854  0.07 
unnamed protein product_17  6569  0.07 
No Hits Found_20   15371  0.07 
Piccolo protein     6717  0.07 
ankyrin 2    17734  0.07 
nuclear transcription factor Y  4189  0.08 
chaperonin containing TCP-1  17165  0.08 
T-cell lymphoma tumor antigen  9876  0.08 
QkI-2      16051  0.08 
No Hits Found_71   6082  0.08 
Regulatory protein TSC-22  5214  0.08 
HSCO protein    12939  0.08 
pre-mRNA splicing factor_2  14844  0.08 
Selenophosphate synthetase 2  13258  0.08 
Sodium pump 3_1   2045  0.09 
klotho secreted isoform   3653  0.09 
unnamed protein product   15622  0.09 





Table 14 Marker selection analysis for hexokinase 1  
Gene Name                      Spot       Score  
                          
hexokinase1     10230  0 
gamma-synergin    14853  0.01 
beta-amyloid precursor   3906  0.02 
Ubiquitin thiolesterase 1   13281  0.02 
NDRG      4966  0.02 
vesicular fusion protein NSF  9664  0.02 
Dihydropyrimidinase related protein-2 12821  0.02 
No Hits Found_20   15371  0.03 
adenosinetriphosphatase   13232  0.03 
valosin-containing protein   1746  0.03 
tubulin, beta 5     2954  0.03 
LEP100 protein     14458  0.03 
ubiquitin-like 3    18010  0.04 
ERO1-like    9129  0.04 
nuclear ribonucleoprotein L  11670  0.04 
EGF-response factor 2   16446  0.04 
SNAP-beta    16210  0.04 
Sodium pump 3_1   2045  0.05 
klotho secreted isoform   3653  0.05 
Dynactin    16239  0.05 
unnamed protein product_17  6569  0.05 
synapsin Iib    14818  0.05 
phosphate carrier protein    12265  0.06 
unnamed protein product _6  16147  0.06 
transcription elongation factor B   1676  0.06 
Neural enolase (NSE)   13011  0.06 
Unknown protein_5   1831  0.06 
retinoblastoma tumor suppressor  9201  0.06 
phosphoglucose isomerase  73  0.07 
Similar to macropain   13235  0.07 
nuclear distribution gene C   17031  0.07 
QkI-2      16051  0.07 
Selenophosphate synthetase 2  13258  0.07 
unnamed protein product    3853  0.07 
sphingosine kinase 1   3703  0.07 
ACTIN, CYTOPLASMIC TYPE 5  4161  0.07 
unnamed protein product _12  2170  0.07 
POL-like    15506  0.07 
unnamed protein product   15622  0.07 
endocrine neoplasia 1    12899  0.08 
ankyrin repeat and SOCS box protein  14767  0.08 
Sodium pump 3    8105  0.08 
SET protein    11620  0.08 
KIAA0605 gene product   13929  0.08 
EST H08032.1     13326  0.08 
tetraspan 3    17122  0.08 
malignant liposarcoma    6875  0.08 
similar to phosphoglycerate mutase 6482  0.09 
No Hits Found_68   7604  0.09 
similar to Eferin    15094  0.09 





Table 15 Marker selection analysis for phosphoglycerate mutase  
Gene Name                      Spot       Score  
                          
similar to phosphoglycerate mutase 6482  0 
Sodium pump 3_1   2045  0.02 
Sodium pump 3    8105  0.02 
Amyloid-like protein 2    12582  0.03 
SNARE     10056  0.03 
transcription elongation factor B   1676  0.03 
beta-amyloid precursor    9607  0.03 
eukaryotic translation elongation factor 1_1 16106  0.04 
Sodium pump 3_2   11249  0.04 
klotho secreted isoform   3653  0.04 
eukaryotic translation elongation factor 1 16149  0.04 
fusion protein attachment protein  8244  0.04 
pre-mRNA splicing factor   9696  0.04 
Neural enolase (NSE)   13011  0.04 
Regulatory protein TSC-22  5214  0.05 
alpha 1 type III collagen   5511  0.05 
similar to Amyloid beta A4   1900  0.05 
No Hits Found_128   4568  0.05 
hypothetical protein _8   487  0.06 
RNA-binding protein FUS    16410  0.06 
extensin     17131  0.06 
PP2A-alpha    3986  0.06 
pre-mRNA splicing factor_2  14844  0.06 
unnamed protein product    3853  0.06 
No Hits Found_56   12987  0.06 
Na/K ATPase_1    2049  0.06 
beta-amyloid precursor   3906  0.07 
calmodulin 2    14543  0.07 
Similar to protein kinase C   6549  0.07 
No Hits Found_20   15371  0.07 
F-box only protein 3   1309  0.07 
VAMP      8081  0.07 
Unknown protein     14486  0.08 
poly(A) binding protein   1670  0.08 
ADAM 12    17139  0.08 
ACTIN, CYTOPLASMIC TYPE 5  4161  0.08 
EST H08032.1     13326  0.08 
No Hits Found_68   7604  0.08 
vesicle associated protein   5128  0.08 
adenosinetriphosphatase   13232  0.08 
malignant liposarcoma    6875  0.08 
Na/K ATPase_3    4949  0.08 
endocrine neoplasia 1    12899  0.08 
hexokinase1     10230  0.09 
agCP3452     8686  0.09 
synapsin Iib    14818  0.09 
Na/K ATPase    1902  0.09 
Pleiotrophin    8479  0.09 
Unknown gene product    17829  0.09 
phosphate carrier protein    12265  0.09 





Table 16 Marker selection analysis for Neural Enolase   
Gene Name                      Spot       Score  
                          
Neural enolase (NSE)   13011  0 
malignant liposarcoma    6875  0.01 
klotho secreted isoform   3653  0.02 
PP2A-alpha    3986  0.02 
ACTIN, CYTOPLASMIC TYPE 5  4161  0.02 
No Hits Found_20   15371  0.02 
Sodium pump 3_1   2045  0.02 
RNA-binding protein FUS    16410  0.03 
beta-amyloid precursor   3906  0.03 
eukaryotic translation elongation factor 1_1 16106  0.03 
Regulatory protein TSC-22  5214  0.03 
unnamed protein product    3853  0.03 
synapsin Iib    14818  0.03 
EST H08032.1     13326  0.03 
tubulin, beta 5     2954  0.03 
Unknown protein_3   17661  0.03 
endocrine neoplasia 1    12899  0.03 
vesicle associated protein   5128  0.03 
No Hits Found_116   14562  0.04 
No Hits Found_56   12987  0.04 
transcription elongation factor B   1676  0.04 
PQBP-1b/c    3258  0.04 
similar to phosphoglycerate mutase 6482  0.04 
tubulin, beta     9603  0.05 
ADAM 12    17139  0.05 
POL-like    15506  0.05 
phosphoglucose isomerase  73  0.05 
tetraspan 3    17122  0.05 
No Hits Found_68   7604  0.05 
beta-amyloid precursor    9607  0.05 
Amyloid-like protein 2    12582  0.05 
Dihydropyrimidinase related protein-2 12821  0.05 
alpha 1 type III collagen   5511  0.06 
similar to hypothetical protein_1  8410  0.06 
gamma-synergin    14853  0.06 
No Hits Found_47   5021  0.06 
hexokinase1     10230  0.06 
retinoblastoma tumor suppressor  9201  0.06 
ubiquitin-like 3    18010  0.06 
SNARE     10056  0.06 
similar to Amyloid beta A4   1900  0.06 
serum deprivation response protein  13473  0.06 
unnamed protein product _6  16147  0.07 
vesicular fusion protein NSF  9664  0.07 
SET protein    11620  0.07 
KIAA0605 gene product   13929  0.07 
Similar to macropain   13235  0.07 
Sodium pump 3    8105  0.07 
fusion protein attachment protein  8244  0.07 
Fas-ligand associated factor 3  7452  0.07 





Table 17 Marker selection analysis for Aldolase C   
Gene Name                      Spot       Score  
                          
aldolase C    3836  0 
PHLDB2    1283  0.07 
NADP-specific isocitrate dehydrogenase 5860  0.07 
unnamed protein product_4  15664  0.07 
vesicle-associated membrane protein 3 1740  0.07 
neurofilament-L    4896  0.09 
Thy-1 antigen    5098  0.09 
elongation factor 1-beta    2131  0.09 
serine incorporator 1    9694  0.1 
vitronectin    11696  0.11 
RIKEN cDNA 1200015A22   3363  0.12 
glutathione S-transferase   10  0.12 
pleiotrophin    8479  0.13 
deoxyhypusine synthase   16197  0.13 
SET domain, bifurcated 1    9877  0.13 
Na/K ATPase_2    17653  0.14 
No Hits Found_25   7453  0.14 
SNARE     10056  0.14 
Na/K ATPase_1    2049  0.15 
No Hits Found_34   2861  0.15 
alpha 1 type III collagen   5511  0.15 
cytochrome b    17687  0.15 
Sigma-adaptin 3b    5121  0.15 
Similar to protein kinase C   6549  0.16 
unnamed protein product_2  2694  0.16 
acyl-Coenzyme A dehydrogenase family 16554  0.16 
tryptophan 5-monooxgenase   1732  0.16 
No Hits Found_84   4336  0.16 
Tyrosine kinase receptor   5022  0.16 
hypothetical protein _8   487  0.17 
endoglin     14721  0.17 
Na/K ATPase_3    4949  0.17 
EH-domain containing 3   4323  0.17 
VAMP      8081  0.18 
SH3BGRL3-likeprotein    2800  0.18 
Unknown protein    14486  0.18 
hydroxyproline-rich glycoprotein   10403  0.18 
Amyloid-like protein 2    12582  0.18 
Na/K ATPase    1902  0.18 
translation elongation factor 1 alpha_1 1751  0.18 
trypsin domain containing 1   10806  0.19 
Alpha1,2-Mannosidase   13854  0.19 
unnamed protein product_1  4379  0.19 
Cloning vector    4125  0.19 
unnamed protein product_9  5958  0.19 
unknown    1805  0.2 
Sodium pump 3    8105  0.2 
F-box only protein 3   1309  0.2 
Transthyretin precursor (Prealbumin)  8007  0.2 
beta actin    5104  0.2 




TNF AP gene expression. We ran qPCR to verify expression profiles for four of these 
genes, CEBPζ, TNF AP, Metalloprotease 1, and GHRHR (Fig. 6). All but TNF AP 
were confirmed by qPCR. However, for TNF AP there was a 10-fold difference in 
mRNA levels between the Fat and Lean line at week 1, which closely correlated with 
expression of the other three genes evaluated. 
Glycolysis was a major biological process altered between the Fat and Lean 
lines, with five out of the ten genes involved with converting glucose into pyruvate 
identified in the microarray analysis (Table 4). Using the KNN algorithm, we 
identified four out of the five genes as being closely linked, which isn’t surprising 
since they are all key genes involved in glycolysis (Fig. 7b and Tables 13-17). From 
this analysis, we identified Klotho, DRP2 and ADAM12 as genes that may interact 
with the glycolytic pathway in the hypothalamus during the divergence of adiposity 
between the Fat and Lean lines. Expression profiles for these three genes remains to 
be confirmed by qPCR. 
Discussion 
In this quantitative trait “obesity” model, microarray analysis revealed 
dynamic changes in gene expression within the hypothalamus before and after the 
development of adiposity. A number of the genes identified with the microarray 
analysis have been previously shown by transgenic or knockout mouse technology to 
directly regulate adiposity or body weight. We also found that genes involved in 
glycolysis were dramatically downregulated in the Fat line relative to the Lean line 
before the development of adiposity, week 1 (Fig. 3a and Fig. 5). Our study also 
contributes novel information by identifying the following: 1) 40 genes that correlate 
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with expression of either the fat or lean phenotype (Fig. 1), 2) downregulation of 
genes involved in glycolysis in the Fat line relative to lean is observed during the 
phase prior to adiposity divergence as well as the phase after adiposity has diverged 
and begun to stabilize between the lines, suggesting that it plays a key role in 
determining genetic susceptibility, and 3) many of the genes which have been shown 
to be associated with adiposity and body weight through transgenic or knockout 
techniques are also associated with genetically induced obesity via genetic selection 
of animal lines.  
Glycolysis and the development of adiposity. 
We have identified differences in genetic selection for genes known to 
modulate 5 out of the 10 steps involved with glycolysis. Glycolytic gene expression 
was downregulated in the hypothalamus of the Fat relative to Lean line at week 1 of 
age, prior to any notable differences in adiposity between the lines.  In a similar 
manner, it has been shown that an enhancement in hepatic glycolysis has also been 
associated with a reduction in obesity 91, which parallels the upregulation in the lean 
line or downregulation in the fat line of glycolytic genes. We found it remarkable that 
5 out of the 10 genes for enzymes regulating glycolysis were identified from the 
microarray. Expression patterns were confirmed for three genes using qPCR (Fig. 5). 
We have also identified three genes which are potentially upstream regulators, 
downstream targets or genes simply expressed in parallel with four of the genes 
involved with glycolysis, Klotho, DRP2 and ADAM12.  
Klotho is a gene that has been associated with regulating energy metabolism. 
Mice lacking Klotho gene expression have almost no white adipose tissue, but normal 
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levels of brown adipose tissue92. Surprisingly, we observed increased levels in the 
Lean line relative to the Fat line before adiposity began to diverge, week 1. However, 
it is plausible that another parameter, like glucose levels could predominantly regulate 
Klotho gene expression. For example, the C1818T polymorphism in exon 4 of this 
gene has been associated with higher fasting plasma glucose level than individuals 
without the polymorphism93. The Lean line does have higher levels of glucose, so it is 
plausible that a similar polymorphism is present in the chicken Klotho gene.  
We have also demonstrated potential links between adiposity, DRP2 and 
ADAM 12. The disintegrin and metalloprotease with thrombospondin motifs 1 94 
have been directly associated with modulating body composition 95 and are present in 
the ADAM 12 gene. Expression patterns of this gene are opposite than predicted at 
week 1, increased expression in the Lean relative to Fat line, since mice lacking this 
motif have been shown to have a lean phenotype. In regards to DRP2, also known as 
CRMP2, the gene is associated with Alzheimer’s disease96,97 and is known to be 
involved with development of the nervous system98.  This is the first report 
associating the function of this gene with energy regulation, specifically glycolysis 
and processes contributing to the divergence of the fat or lean phenotype, suggesting 
that further investigation for the role of DRP2 in glycolytic metabolism is warranted.  
Homologous genes in knockout or transgenic mice were identified by the microarray 
analysis 
 Many genes have been identified to be involved with regulating body 
composition through genetic manipulations. Analysis of the microarray data 
identified some of the same genes previously known to modulate adiposity, and the 
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data support the hypothesis developed for which genes interact, upstream or 
downstream, of one another. TNFα associated genes were another family of genes 
that had expression differences between lines. TNFα is a cytokine secreted from 
many cell types, including adipocytes, and has been shown to act on the 
hypothalamus to suppress appetite 99. We demonstrated an upregulation for genes 
related to TNFα signaling in the Lean relative to Fat line, potentially explaining the 
decreased adiposity in the Lean relative to Fat line. 
 The TRAF-1 molecule has been associated with gene expression for the sweet 
taste receptor (T1R1), which is also present in the lining of the small intestine and is 
associated with glucose uptake 100. The Fat and Lean lines have differences in glucose 
levels, with the Fat line having lower plasma glucose and higher plasma insulin 
relative to the lean line 90. Since expression of T1R1 and TRAF-1 are lower in the Fat 
relative to Lean line, this suggests that T1R1 in the hypothalamus may be associated 
with TRAF-1 to modulate glucose uptake in the neuron, in a similar manner as 
demonstrated in the intestine. TRAF-1 was also associated in our current study with 
GHRHR and 5-HTP, the rate-limiting enzyme for serotonin production. Both of these 
genes have been previously implicated in regulating body composition101,102 and 
indirect relationships have been shown to exist between TNFα and GHRH or 5-HTP. 
For example, by blocking serotonin receptors the antitumor effects of TNFα were 
attenuated 103. We demonstrate here that decreased levels of 5-HTP mRNA correlate 
with decreased levels of TRAF-1 mRNA in the Fat relative to Lean line.  In regards 
to GHRH, mice with deficits in GHRH signaling were not able to increase mRNA 
expression for GHRHR or TNFα after virus treatment, suggesting that a direct 
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relationship between the two genes may exist 104. Therefore, future investigations to 
further characterize these interactions are warranted.     
 Our analysis also suggests that TNF AP may interact with CEBPζ, CEBPα 
and β have been associated with adipocyte differentiation 105, and here we show that 
hypothalamic CEBPζ may also be associated with the divergence of adiposity in the 
Fat and Lean lines, with CEBPζ mRNA levels being greater in the Fat relative to 
Lean line. Lastly, Metalloprotease 1 was also identified in the present study as a 
candidate gene associated with TRAF-1. Interestingly, it has been found that tissue 
inhibitor of metalloprotease 1 is elevated in obese children, resulting in lower levels 
of metalloprotease 1 106. This trend corresponds with the increased levels of 
metalloprotease 1 mRNA observed in the hypothalamus of the Fat line relative to 
Lean line at week 1 of age. It has also been shown that TNFα elevates the levels of a 
disintegrin and metalloprotease with thrombospondin motifs 1 94, which has been 
directly associated with modulating body composition 95, which in combination with 
our current findings suggests that TNFα may interact with or regulate expression of 
metalloprotease 1 to modulate body composition. 
Allelic segregation and genetic influences 
The data presented here further support the possibility that genotype may 
influence development of the obese phenotype by regulating hypothalamic expression 
patterns of genes in ways not previously predicted. This may occur by allelic 
segregation occurring in genes presented in this paper or it may be due to alleles of 
the unidentified genes that modulate expression for the genes identified here. 
Furthermore, it is possible that differential expression in the hypothalamus of genes 
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related to TNFα signaling processes, CEBP and glycolysis in the Fat relative to Lean 
line prior to the onset of adiposity serve to establish a set point for long-term 
regulation of body fat stores during a critical developmental period. As adiposity 
develops and the adipose mass set point evolves and matures over the first 9 weeks, 
these genes may function to establish homeostatic mechanisms by differentially 
modulating one of the following: 1) metabolism, 2) nutrient utilization or 3) body 
composition set point.  Furthermore, during a critical period shortly after hatch/birth, 
expression patterns of TNFα signaling processes and glycolytic genes may serve to 
regulate development of the fat or lean phenotype, or this may occur in parallel. The 
altered gene expression at week 1 of age, prior to any differences in adiposity, may 
modulate neuronal synaptic development to regulate the long-term body fat “set-
point” at this age, which is further supported by the fact that neural pathways between 
nuclei in the hypothalamus are not established until postnatal day 8 in the mouse 107. 
Furthermore, we have identified a large set of genes that are differentially regulated 
due to the allelic segregation from 21 generations of selective breeding and which 
may potentially interact to regulate energy homeostatic mechanisms. 
 Quantitative trait animal models are useful for identifying novel candidate 
genes that regulate energy homeostasis.  For example, one rat model was bred to be 
susceptible (DIO) or resistant (DR) to dietary-induced obesity, and has been very 
useful for elucidating how environment and genotype interact to influence the 
development of obesity 21.  Here we present a model that allowed us to study 
genotype-regulated differences during development of adiposity, independent of 
environmental variables, suggesting that this chicken model has the potential to 
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elucidate the underpinnings of genotype induced human obesity. Furthermore, this 
study has a high relevancy for human implications since the chicken genome has a 
greater synteny with the human genome than does the mouse 108,109. Thus, here we 
utilized microarray analysis to investigate potential polygenic expression patterns and 
identify novel candidate genes that may contribute to the development of genotype 




Chapter 3: Differential Expression of Anorexigenic 
and Orexigenic Genes in Fat and Lean Lines 
Abstract 
Gene interactions in the hypothalamus may regulate development of obesity, 
since this brain region modulates food intake, metabolic rate and body weight. We 
characterized gene expression in the hypothalamus during development of adiposity 
in fat and lean chicken lines, selectively bred for high and low percent body fat that 
diverges independent of environmental influences. Using quantitative real time PCR 
we determined gene expression patterns before and after differences in adiposity 
diverge between the lines for 14 orexigenic and anorexigenic genes. Neuropeptide Y 
(NPY) mRNA was decreased and Pro-opiomelanocortin (POMC) mRNA was 
increased in the fat relative to the lean line, consistent with known responses to 
adipose signals. Genes demonstrating an interesting expression profile were 
Thyrotropin Releasing Hormone (TRH), Brain-Derived Neurotrophic Factor (BDNF), 
Tyrosine kinase receptor B (TrkB), and Leptin Receptor (LEPR) since they 
demonstrated differences in expression between the lines prior to any differences in 
adiposity (week1). Thus, these genes might be key anorexigenic and orexigenic 
neuropeptides that modulate the divergence of an obese phenotype prior to alterations 
in levels of adiposity. Surprisingly, differential expression between or within lines for 
Melanocortin-4 receptor mRNA was not observed. This suggests that genotype may 
influence development of the obese phenotype or interact with hypothalamic gene 
expression patterns regulating anorexigenic and orexigenic genes which may program 




In humans and other species, heritability influencing genetic susceptibility 
contribute to the development of an obese phenotype 9. Increased adiposity may arise 
from genotype variations, which contribute to susceptibility for developing the 
phenotype, and environmental factors, such as diet, exercise, and social factors 110.  
Altering neuropeptide expression in the hypothalamus may disrupt the mechanisms 
that serve to regulate energy homeostasis, thereby altering the ability to maintain a 
constant level of energy stores over time in the form of fat 8,111. More specifically, 
neuropeptide expression in the hypothalamus has been identified as a key regulator of 
body weight and food intake processes based on lesion studies that ablate either the 
ventromedial hypothalamus or the lateral hypothalamus 4,5. Although both genetic 
and environmental factors contribute to disrupting energy homeostasis, alterations in 
environmental factors are not always essential to disrupt energy regulation, and 
genetic factors alone can give rise to an obese phenotype 112.  
Many neuropeptides in the hypothalamus have been implicated in energy 
homeostasis, some increasing fat deposition (orexigenic/anabolic) and some 
decreasing fat deposition (anorexigenic/catabolic). Several candidate neuropeptide-
containing pathways in the hypothalamus have emerged as mediators for energy 
homeostasis. Under normal conditions, these peptides function in a complimentary 
fashion to maintain a dynamic equilibrium of energy homeostasis with orexigenic 
pathways that serve to increase food intake, increase fat deposition and decrease 
energy expenditure  (e.g. Neuropeptide Y, NPY; Agouti-related protein, AGRP; 
Orexin, ORX; and melanin concentrating hormone, MCH) and anorexigenic 
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pathways that decrease food intake, decrease fat deposition and increase energy 
expenditure (e.g. Corticotropin releasing hormone, CRH; Thyrotropin releasing 
hormone, TRH; Cocaine- and amphetamine-regulated transcript, CART; and 
Proopiomelanocortin, POMC) 8,113-115.  Although glucocorticoids have an anabolic 
effect on adipose tissue, we have chosen to define CRH as a catabolic neuropeptide 
based on regulation by adipose singals. CRH mRNA levels increase in order to 
decrease energy intake as leptin and insulin levels increase8. Although monogenic 
alterations can result in food intake and/or body weight disregulation, it remains to be 
determined which polygenic alterations in anorexigenic and orexigenic gene 
expression contribute to altered phenotypic states like obesity. 
Novel candidate genes that regulate energy homeostasis can be identified by 
using quantitative trait animal models selectively bred for a phenotype.  Rats bred to 
be susceptible (DIO) or resistant (DR) to dietary-induced obesity have been very 
useful for elucidating how environment and genotype interact to influence the 
development of obesity21.  Here we present a chicken model that allows us to 
elucidate genotype induced obesity, independent of environmental variables.  
Furthermore, the chicken genome has more synteny with the human genome than a 
rodent species108,109, further supporting how relevant and useful these data are for  
potential clinical implications by identifying more mechanisms that contribute to 
obesity susceptibility based on genotype.  
Therefore, we utilized Fat and Lean chicken lines in order to determine 
anorexigenic and orexigenic gene expression that correlated with the development of 
adiposity.  Selective breeding for fat and lean phenotypes over 21 generations 
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allowed segregation of alleles regulating body composition in these lines15.  More 
importantly, these phenotypes develop independently of environmental and 
behavioral influences (i.e. a high fat or high calorie diet, level of food intake) 19,84,85, 
suggesting that development of adiposity is based on genotype differences alone. 
Neuropeptides in the hypothalamus are known to modulate energy homeostasis in the 
same manner in both chickens, rodents and humans116. Here we dissociate genetic 
from environmental influences on adiposity by utilizing Fat and Lean lines of 
chickens, which allows us to identify genes that regulate genetic susceptibility for 
body composition 19,84. This is an important dissociation because it is often difficult to 
separate genetic influences regulating increased adipose mass without simultaneously 
altering food intake.     
In order to better elucidate the underlying genetic mechanisms that contribute 
to the development of the “obese” phenotype, independent of altering food intake, we 
have characterized anorexigenic and orexigenic gene expression in the hypothalamus 
prior to and after differences in adiposity in this unique animal model. We predicted 
that increased expression of anorexigenic neuropeptides, such as POMC, CRH, TRH 
and CART, with simultaneous suppression of orexigenic neuropeptides such as NPY, 
AGRP, ORX and MCH would be observed in the fat relative to the lean line in order 
to compensate for increased adipose fat, since previous work has demonstrated that 
increased adipose mass results in increased expression of POMC and decreased 
expression of NPY and AGRP 8.  However, if the predicted compensatory patterns of 
expression for either the anorexigenic or orexigenic genes are not observed, then it is 
plausible that these genes could contribute to the underlying mechanisms that result in 
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either a fat or lean phenotype.  Prior to this study, it was unknown whether 
differences in anorexigenic and orexigenic neuropeptide expression would develop 
prior to or after divergence in adiposity.  It also remained to be determined whether 
differences in some or all of these genes would be observed independent of 
alterations in food intake.  Our results demonstrate that 8 out of the 14 genes tested 
have altered expression, which occurs independently of altered food intake, as 
previously demonstrated in this model of adiposity19,84,85. Four of the genes were 
expressed in a direction different from that predicted and two of these genes were 
differentially expressed prior to the onset of adiposity divergence between the two 
lines.  These results help to elucidate the mechanisms that may contribute to 
development of genetically based adiposity. 
 
Materials and Methods 
Animals and tissue preparation. 
  Genetically selected Fat and Lean chicken lines, developed at INRA, were 
used 19. Selective breeding for about 21 generations occurred by choosing animals 
with the greatest and lowest amount of abdominal fat with similar body weight at 9 
weeks of age. Males from each line were kept and reared in floor pens (4.4 x 3.9 
meters). Fat (16) and Lean (16) chickens were reared together in the same pen to 
eliminate environmental differences. They were given ad libitum access to food and 
water at all times using conventional starter (0-3 weeks) and grower (3-11 weeks) 
pellet diets. The light/dark cycle was: 24 hr of light for the first two days and then 14 
hr of light and 10 hr of dark thereafter.  
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Hypothalami were collected from Fat and Lean animals at weeks 1, 3, 5 and 7 
of age in order measure differences in gene expression correlating with the 
development of the phenotypes. Adiposity differences diverged between the Fat and 
Lean line by week 3 of age. There were no differences in adiposity at week 1 of age, 
providing a baseline to compare physiological alterations before and after the onset of 
excessive adiposity. Animals were sacrificed with the hypothalamus being 
immediately dissected and snap frozen in liquid nitrogen (n=4 for each age and 
group) and stored at –80 ºC until further processing. Commercial coated-tube 
radioimmunoassays were used to measure plasma levels of thyroid hormones (T3 and 
T4) (MP Biomedicals, Solon, OH). All procedures were handled in accordance with 
the Institutional Animal Care and Use Committee at the University of Maryland, 
University of Delaware and the Institute de Nationale Recherches Agronomique. 
Primer design and validation.  
All primers were designed using Primer Express (v 2.0, Applied Biosystems, 
Foster City, CA) and designed using a homologous region of chicken cDNAs when 
aligned with the same gene sequence for the mouse.  Primers were 18-30 nucleotides 
in length with a melting temperature between 58-64 ºC or 69-72 ºC.  The PCR 
product was between 100 and 150bp.  Forward and reverse primer sequences are 







GENE Sense primer Antisense primer 
AGRP 5’AGAGCGGACCGTGAGGACACTT3’ 5’GTTGGCATTTCCTCCCAAAGGA3’ 
AMPK 5’TCTCCGCGGTGGATTACTGT3’ 5’AGCAGCACGTTCTCTGGTTTC3’ 
BDNF 5’TGGGTAACAGCAGCGGAGAA3’ 5’TATTGCTTCAGTTGGCCTTTAG3’ 
CART 5’CACCTGCCCGAACTTCTTCTCGTA3’ 5’CCCGAGAGAAGGAGCTGATCGA3’ 
CCKr 5’CGCACCGTCACCAACTCTTT3’ 5’GAAGACGAAGGTGCCCATGA3’ 
CRH 5’CACAGCAACAGGAAACTGATGGAAA3’ 5’AAAGAGGTGACATCAGAGCAGCACTATG3’ 
LEPR 5’AAAACCCAGAGCGTAGCGTCCAA3’ 5’TTGCTTACGCGATCGTTCACAAG3’ 
MC4R 5’CGGGAGGCTGCTATGAACAA3’ 5’AGCTGATGATGCCCAGAGTCA3’ 
MCH 5’GATTCCAGACATGACTTCTCAAATCATGGT3’ 5’TCAGTGTCAGCTGGAAAAGCAATGG3’ 
NPY 5’GGGAAAGCACAGAAAACATTCC3’ 5’AAATCCCATCACCACATCGAA3’ 
Orexin 5’CACGCTGAGAAGGACCTGACCAA3’ 5’CCAGGGCCACAGGGAGGTATTTAA3’ 
POMC 5’AGGGACCTCAGGGATCATCAA3’ 5’TGTTCAAGGGCAGGTTGGA3’ 
TRH 5’AGCATCTTTTGGAGACATTCAG3’ 5’CAGCTCCAGGTAGTTGACAAGGT3’ 
TrkB 5’GTCCTGGGTGCTCACTAACCTT3’ 5’TTATGGTTAACGAGGCAGGATTC3’ 
GAPDH 5’AAGGAGTGAGCCAAGCACACA3’ 5’TCACTGCAGGATGCAGAACTG3’ 
Β-actin 5’CCCAAAGCCAACAGAGAGAAG3’ 5’ACCATCACCAGAGTCCATCAC3’ 
Table 1. Primer sequences used for qPCR.
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RNA isolation and cDNA preparation.  
Individual tissue samples were homogenized and total RNA extracted with 
Rneasy Midi kits (Qiagen, Valencia, CA) according to the manufacturer’s protocol. 
Extracted RNA was quantified using UV absorbance (260nm) and using a 
bioanalyzer (Agilent Technologies, Palo Alto, CA). 1µg total RNA was used to create 
the cDNA using the stated protocol for Superscript III reverse transcriptase 
(Invitrogen, Carlsbad, CA) and an oligo(dT) primer. Blank cDNA was made as 
described in order to have a negative control which measures genomic DNA 
contamination with total RNA samples, but with no reverse transcriptase added. 
mRNA levels were quantified using 2µl of diluted cDNA (1:200) in a 20µl 
quantitative real time PCR (qPCR) reaction using invitrogen recombinant Taq, 2X 
PCR buffer containing 100 mM KCl, 20 mM Tris-HCl (pH 9.0), 0.2% triton-X 100, 
3.8 mM MgCl2, 0.12 U/µl Taq Polymerase, 400 nM dNTPs, 40 nM fluorescein, and 
SYBR Green I Nucleic Acid Gel Stain diluted 1:10,000 (all Invitrogen, Carlsbad, 
CA)  and analyzed with the iCycler iQ Real-Time PCR Detection System (Bio-Rad, 
Hercules, CA) .  In all cases, a three-step PCR cycle was used: initial denaturation at 
95 ºC for 3 min followed by 40 cycles of 94 ºC for 45s, 60 ºC for 45s and 72 ºC for 
45s, followed by melting temperature analysis at 94 ºC in order to verify that one 
PCR product was amplified. PCR products were verified by dissociation curve 
analysis and gel electrophoresis for the appropriate size.   
Statistical analysis and graphical display of data 
The qPCR output data provided a Ct value for the threshold cycle.  The Ct 
value represents the threshold cycle, which is achieved when the amount of amplified 
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product reaches a fixed threshold for fluorescence due to binding of SYBR green to 
the double-stranded PCR product. Given that each cycle is on a log scale the data 
were transformed to a ∆Ct value by subtracting the blank Ct value from the sample Ct 
value.  The ∆∆Ct value was generated using geNorm software and methods 88.  
Briefly, the data were first transformed to a ∆Ct value by subtracting the sample Ct 
value from the sample with the highest expression level in order to control for 
amplification efficiency. The ∆∆Ct value was then calculated by normalizing gene 
expression to two housekeeping genes, β-actin and GAPDH.  
Differences in gene expression for all experiments were tested using a two-
way analysis of variance (ANOVA), with main effects of Line and Age as well as the 
Line-by-Age interaction tested, using the Mixed procedure in SAS, with post-hoc 
comparisons by age performed using the PDIFF procedure (Statistical Analysis 
System, v.8.02, SAS Institute, Cary, NC). Values reported are means ± SEM, and P 
<0.05 was required for statistical significance.  
 
Results 
Phenotype difference between the Fat and Lean lines 
Phenotype differences between the Fat and Lean lines were observable for 
abdominal fat and the abdominal fat to body weight ratio (%), but no differences 
between the lines were apparent for body weight (Table 4, Chapter 2). The abdominal 
fat levels were not different between the two lines at week 1 of age, but differences 
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began to emerge by week 3 and maximal divergence was observed by week 7, 
reaching a plateau thereafter. By 7 weeks of age the Fat line had 266% more 
abdominal fat than the Lean line, which is a 2.8 fold difference in abdominal fat to 
body weight ratio (Table 4, Chapter 2). We observed differences in T3 levels prior to 
any differences (week 1) in adiposity and immediately after adiposity began to 
diverge between the lines (week 3). The modestly increased T3 levels (Fig. 1a) are 
similar to morbidly obese euthyroid humans 44, as well as previous observations in the 
Fat and Lean lines 83. We did not observe any difference in T3 at weeks 5 and 7 (Fig. 
1a), and there were no differences observed for T4 between the lines (Fig 1b).  
Hypothalamic anorexigenic and orexigenic gene expression between the Fat and 
Lean lines 
We screened hypothalamic genes (Figs. 2 and 3) known to modulate energy 
homeostasis in the same manner as in mammals 116 and identified 8 genes which 
differed according to increased adiposity: BDNF, TrkB, TRH, LEPR, POMC, AGRP, 
NPY and CRH (Fig. 2 and 3). Overall, 8 of the 15 genes tested were differentially 







Figure 1. Plasma Thyroid Hormone levels in Fat and Lean Lines during 
development of adiposity. a-b. Endogenous Triiodothyronine levels (T3) (a) and 
endogenous thyroxing levels (T4) in Fat and Lean lines at weeks 1, 3, 5 and 7 (n = 4).  
*p<0.05 and **p<0.01 fat relative to lean line for the same age. 






Figure 2. Anabolic gene expression in the hypothalamus of Fat and Lean lines. a-
f, Quantification of hypothalamic AGRP (a), NPY1 (b), MCH (c), Orexin (d), AMPK 
(e), and β-actin (f) mRNA levels from Fat (filled bar) and Lean (open bar) lines 
weeks 1, 3, 5 and 7 of age (n = 4) by qPCR analysis. lDenotes an overall difference 







Figure 3. Anorexigenic neuropeptide mRNA levels in Fat and Lean Lines during 
development of adiposity. a-j. TrkBl (a),  BDNFl (b), LEPR (c), TRHl (d), CRH (e) 
POMCl (f), CCKr (g), CART (h), GAPDH (i), and MC4R (j)  by qPCR from Fat 
(filled bar) and Lean (open bar) lines weeks 1, 3, 5 and 7 of age (n = 4). * p<0.05, 
**p<0.01, # p<0.055 Fat relative to Lean line for the same age. lDenotes an overall 
difference between lines. 
 91 
 
The two orexigenic genes differentially expressed between the lines were AGRP and 
NPY. AGRP expression was greater in the Fat line relative to the Lean line at the 
time point when adiposity began to emerge, week 3 of age (Fig. 2a). Surprisingly, 
NPY gene expression was not expressed in the predicted direction, being greater 
overall in the Lean line relative to the Fat line (Fig. 1b). There were no differences in 
gene expression for MCH, Orexin, and AMPK (Fig 2c-e, respectively). β-actin and 
GAPDH gene expression after normalization were not different between the lines 
(Fig. 2f and 3k, respectively).  
There were six anorexigenic genes differentially expressed between the two 
lines. Prior to and after the onset of increased adiposity, BDNF was decreased in the 
Fat line (Fig. 3b), suggesting that a reciprocal relationship may exist in vivo between 
plasma T3 levels and hypothalamic BDNF expression.  Additionally, we also  
observed subsequent suppression of TrkB mRNA at weeks 3 and 5 (Fig. 3d) and TRH 
at week 5 (Fig. 3a) in the Fat relative to Lean Line. LEPR mRNA was increased in 
the Fat relative to Lean line at week 1, and by week 5 LEPR was decreased in the Fat 
line (Fig. 3c). Interestingly, the profile of LEPR correlated with TrkB expression at 
week 5 of age, suggesting a potential biological interaction between the genes since 
expression profiles are similar. POMC gene expression was greater in the Fat relative 
to Lean line over all time points, which was expected (Fig. 3f).  CART gene 
expression had a trend toward being greater in the Fat relative to Lean line, however 
it was not significant (Fig. 2g, p=.056).  MC4R and CCK receptor were not 





In this quantitative trait model of adiposity, with no simultaneous alterations 
in food intake 84,117-119, we detected differences in anorexigenic and orexigenic gene 
expression before and after differences in adiposity began to  diverge between the 
lines. Increased adiposity developed by week 3 in the Fat relative to Lean line, with 
no differences in adiposity at week 1 of age. We identified one hormone, T3, and 8 
genes which differed according to increased adiposity: BDNF, TrkB, TRH, LEPR, 
POMC, AGRP, NPY and CRH (Fig. 1). CART only approached significance 
(p=.055) (Fig. 1h). The modestly increased T3 levels resemble those in morbidly 
obese euthyroid humans 44, as well as previous observations in the Fat and Lean 
lines83.  
During energy homeostasis, anorexigenic and orexigenic genes function to 
maintain steady state levels of adipose tissue. As adipose stores increase, 
anorexigenic signals also increase and orexigenic signals decrease. Thus, if these 
signals are working in a normal physiological fashion we would expect anorexigenic 
expression to be increased and orexigenic expression to be decreased in the Fat 
relative to the Lean line. However, increased adiposity often results when these 
signals become miss regulated and this appears to be the case for the Fat and Lean 
lines. An example of miss regulation is mice lacking the ability to express an 
anorexigenic gene, BDNF, in the brain after development. These mice are unable to 
properly compensate for increased adipose mass and become about three times 
overweight relative to a mouse expressing BDNF in the brain35, with adult onset 
obesity also appearing in heterozygous mice 30. Therefore, hypothalamic gene 
 93 
 
expression levels based on genotype, not the environment, may occur due to a point 
mutation or polymorphism in the same gene or another gene that modulates 
expression of the anorexigenic/orexigenic gene, to compensate for the increased 
adiposity. Here we show that T3 as well as BDNF and LEPR mRNA levels are 
different between the lines prior to any adiposity differences. We also show that 
NPY, POMC, LEPR and T3 expression levels are in the direction opposite to that 
predicted by prior characterization of gene function, suggesting dysregulation of these 
genes in this model of adiposity. 
No differences between the lines were observed for MC4R, MCH, Orexin, 
CCKr, and AMPK, possibly because there were no differences in food intake between 
the two lines or because altered expression of these genes is not necessary to induce 
differences in adiposity in this quantitative trait model. CART expression values had 
a trend toward significance. Differences in hypothalamic gene expression between the 
Fat and Lean lines were observed in both the predicted direction and the direction not 
predicted.  Differences in the predicted direction for catabolic/anorexigenic 
neuropeptides were observed for BDNF at weeks 1, 3, and 5, TrkB at week 5, TRH at 
week 3, and for LEPR at week 5 of age, with the Lean line having greater mRNA 
expression levels relative to the Fat line. Overall POMC expression, LEPR at week 1 
of age and T3 at weeks 1 and 3 of age were not in the predicted direction, being 
greater in the Fat line relative to Lean line. However, since POMC mRNA translation 
results in 5 different protein products, due to enzymatic cleavage, the αMSH levels in 
the hypothalamus may remain unchanged. Predicted differences for anabolic/ 
orexigenic neuropeptides were observed for AGRP, with the Fat line being greater 
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than the Lean line. Surprisingly, NPY, which is also an anabolic gene, was expressed 
at greater levels in the Lean line relative to the Fat line. It is probable that gene 
expression levels for anabolic and catabolic neuropeptides not in the predicted 
direction (dysregulation) could contribute to physiological alterations that regulate 
development of either the fat or lean phenotype. Alterations in genetic expression in 
the Fat relative to Lean line may be attributable to the following physiological 
changes: 1) thyroid hormone feedback from or to the hypothalamus, 2) adiposity 
signals (i.e. leptin or insulin), 3) fuel partitioning and metabolic pathways, and 4) 
polygenic expression patterns attributable to allelic segregation during the selective 
breeding over 21 generations. 
Hypothalamic regulation and adipose signals 
 Signals arising from adipose tissue, such as leptin and insulin, have been 
known to alter neuropeptide expression in the hypothalamus 120 and the data 
presented here also suggest that adiposity signals, and the corresponding 
hypothalamic receptor, may influence the development of these phenotypes.  For 
example, binding of leptin to the LEPR has been shown to up-regulate POMC mRNA 
expression and down-regulate NPY mRNA expression 121. Given that LEPR mRNA 
levels are increased in the Lean relative to Fat line at week 5 this suggests that LEPR 
signaling may also be upregulated which would result in upregulate POMC and 
downregulate NPY gene expression at this age. However, our findings suggest that 
LEPR signaling processes may not be functioning as predicted, since POMC levels 
are increased and NPY levels are decreased at all ages in the Fat relative to Lean line. 
It is also possible that the POMC and NPY gene sequences have a mutation that 
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prevents them from responding to the leptin receptor signal or that there is another 
unknown protein that out competes the LEPR signal. In support of this hypothesis, it 
has been shown that liver leptin levels are increased 1.7 fold in the Fat line relative to 
the Lean line 122, but a controversy about the validity of this identified chicken leptin 
sequence exists 123.  Regardless, the avian LEPR has been accurately sequenced 124.  
As adiposity diverged between the two lines, interesting expression profile 
differences between the lines were observed for LEPR and BDNF.  At week 1 of age 
LEPR expression was increased and BDNF expression decreased in the fat relative to 
lean line.  Decreased expression of BDNF has been associated with development of 
an obese phenotype 32,35.  However, it has not been previously shown that decreased 
BDNF expression contributes to the development of the obese phenotype without 
alterations in food intake, and our results indicate that hypothalamic BDNF gene 
expression may affect accumulation of body fat without altering food intake. 
Additionally, it was surprising that LEPR mRNA levels switched directionality over 
time as adiposity diverged between the two lines. Therefore, it is plausible that LEPR 
gene expression may be regulated at week 1, prior to differences in adiposity, by a 
mechanism independent of adiposity signaling and by week 5 gene expression may be 
mediated by adiposity signals. The gene expression levels may also be representative 
of leptin signaling via LEPR. The possibility that LEPR signaling may not be able to 
elicit its normal anorectic action at week 1 of age is further supported by the 
observation that leptin does not exert an anorectic effect until after postnatal day 9 in 
the mouse 125. 
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Metabolism and fuel partitioning 
Metabolism is likely to be a major contributing factor to the different 
phenotypes between the lines, as differences in body fat occur in the absence of 
differences in food intake. Gene expression for TRH and CRH were different 
between the lines, which suggests that there may be differences in the hormonal 
feedback circuitry, especially since plasma T3 levels were different. In fact, it has 
been previously shown that thyroid hormone levels are different between the Fat and 
Lean lines, with T3, but not T4, being greater in the Lean line at week 9 of age, but not 
at week 16 or 34 83. Additionally, corresponding with the increased levels of T3 in the 
Fat relative to Lean line at weeks 1 and 3, maximal divergence in fattening occurs 
between the two lines over developmental weeks 3–7, previously shown and present 
data84,117. Furthermore, T3 was decreased in the Fat relative to the Lean line in the fed 
state and refed state after a fast, but not in the fasted state alone 119. However, it must 
be noted that differences in thyroid hormone levels between the lines are minimal and 
are not sufficient on their own to account for differences in body fat between the 
lines. In contrast to TRH, CRH was significantly decreased in the Fat relative to Lean 
line (Fig. 3e), which is surprising since both corticosterone levels and corticosterone 
sensitivity remained unchanged between the two lines, including fed and fasted states 
118,119. However, it has been shown that decreased T3 levels can modulate expression 
of CRH levels 126, which is a plausible explanation for why CRH mRNA levels are 
different in the hypothalamus despite no alterations in plasma corticosterone between 
the Fat and Lean lines.  
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The Fat line has lower plasma glucose and higher plasma insulin levels 
relative to the Lean line between weeks 3 and 5 (Table 4, Chapter 2), and around 6 
and 11 months of age as which may contribute to metabolic alterations influencing 
the fat or lean phenotype between the lines 90. This pathway also has the potential to 
contribute to the differential expression observed for BDNF and LEPR at week one, 
since increased glucose levels are present in the Lean line from hatch, with no 
alteration in insulin at this age 117.  Furthermore, the glucose-insulin imbalance is 
partly attributable to altered signaling in the liver, but not muscle tissue 127, 
suggesting that metabolic utilization and fuel partitioning in the liver may contribute 
to phenotype differences and hypothalamic gene expression patterns. 
Hyperphagia and energy utilization, such as metabolizability or expenditure 
(i.e. basal metabolic rate, maintenance and dietary induced thermogenesis) 84,85,117-119 
are not factors contributing to phenotype differences between the lines. However, 
differences in metabolic pathways and fuel partitioning might be a mechanism that 
contributes to phenotype differences.  For example, both lipid and protein metabolism 
are different between the lines 128 given that the Fat line showed decreased ability to 
retain protein relative to the Lean line, which could be in part due to differences in 
nitrogen metabolism 85. It has also been shown that lipogenesis was higher in the Fat 
relative to the Lean line when animals are fed a low fat diet 118. In fact, these 
differences in fuel partitioning and lipogenesis could contribute to differences in 
hypothalamic gene expression, since it has been previously shown that a high-fat diet 
can decrease BDNF levels in the brain 91,129-131, suggesting that future characterization 
 98 
 
of interactions between dietary properties and hypothalamic BDNF expression in the 
Fat and Lean lines are well deserved.   
Allelic segregation and genetic influences 
The data presented here further support that genotype may influence 
development of adiposity by regulating hypothalamic expression patterns of 
anorexigenic and orexigenic genes in ways not previously predicted. Furthermore, it 
is possible that differential expression of hypothalamic BDNF and LEPR in the Fat 
relative to Lean line prior to the onset of adiposity might serve to establish a “set 
point” for long-term regulation of body fat stores during a critical developmental 
period. As adiposity develops and the adipose mass set point evolves and matures 
over the first 7 weeks, these genes function to establish homeostatic mechanisms by 
differentially modulating one of the following: 1) metabolism, 2) nutrient utilization 
and 3) body composition.  Furthermore, during a critical period shortly after 
hatch/birth expression patterns of hypothalamic anorexigenic and orexigenic 
neuropeptides may serve to regulate development of the fat or lean phenotype, which 
is further supported by the fact that neural pathways between nuclei in the 
hypothalamus are not established until postnatal day 8 in the mouse 107.  Lastly, we 
have identified a small set of genes that are differentially regulated due to the allelic 
segregation from 21 generations of selective breeding, and this finding elucidates one 
potential polygenic expression pattern that may contribute to the fat or lean 
phenotype.  
Here we dissociate genetic from environmental influences on obesity by 
utilizing Fat and Lean chickens selectively bred for phenotype over 21 generations.  
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We propose that genetic factors influencing body composition involve interactions 
between BDNF and thyroid hormone. In vivo data presented here demonstrate that 
alterations in BDNF and T3 during progression of adiposity may be one mechanism 
of genetic susceptibility for an obese phenotype. 
Fat and Lean line data suggest that BDNF or T3 levels could serve as the 
primary signaling factor to initiate hypothalamic gene expression during the different 
stages of adiposity development, since before and at the onset of adiposity divergence 
(week 1 and 3), plasma T3 was increased and hypothalamic BDNF expression was 
decreased in the Fat relative to Lean line. Additionally, at week 3 hypothalamic TRH 
mRNA levels were suppressed in the Fat line, suggesting that either T3 could inhibit 
expression of TRH in the Fat line (Fig. 1e) or increased BDNF expression in the Lean 
line could increase expression of TRH (Fig. 1f). Although at first glance it might 
seem surprising that TRH levels were not elevated until week 5, it should be noted 
that plasma T3 levels need to increase 1.6 fold in order to reduce pro-TRH levels 47. 
Also, Deiodinase 2 is not present in the paraventricular nucleus where TRH neurons 
are located, which suggests that TRH neurons may only be responding to plasma T3 
or to other brain regions that first convert T4 to T3 (e.g. tanycytes) 45. Finally, at week 
5 of age, hypothalamic BDNF mRNA levels continued to increase in the Lean 
relative to Fat line. It is still unknown whether BDNF or T3 initiates the differential 





Chapter 4: BDNF and Thyroid Hormone: A Tipping Point 
That May Regulate Levels of Body Fat 
Abstract 
Genetically related obesity results from altered states of energy metabolism, 
often arising from defects in hormonal and neuropeptide signaling 8.  Alterations in 
food intake 21, inherited genetic factors 9 and hormone levels contribute to energy 
homeostasis and obesity.  Previously, we utilized an animal model to identify 
candidate genes associated with the divergence of adiposity in genetically selected 
Fat and Lean animal lines, independent of alterations in food intake. Differences in 
candidate gene expression occurred simultaneously with alterations in both plasma 
thyroid hormone levels and Brain-Derived Neurotrophic Factor (BDNF) expression 
in the hypothalamus of the brain.  Differential expression of BDNF contributes to 
both obesity and anorexia in humans 33,37,63. Conditional mutant mice lacking BDNF 
in the brain after development also demonstrate severe obesity 35. Additionally, 
modestly elevated levels of thyroid hormone, triiodothyronine (T3), have been 
observed in morbidly obese euthyroid humans 44. The interactions between thyroid 
hormone and BDNF that contribute to energy stored as fat have not been extensively 
studied and are currently unknown. We confirmed interactions between BDNF and 
the hypothalamic-pituitary thyroid axis in vitro and identified leptin receptor (LEPR), 
Pro-opiomelanocortin (POMC), Agouti related protein (AGRP) and 5-tryptophan 
hydroxylase (5-HTP) as additional targets of BDNF or T3 in cell culture. These genes 
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may interact with BDNF and T3 to modulate development of a genetically induced fat 





Disrupting energy homeostasis leads to an obese phenotype affecting about 
100 million adults and 22 million children worldwide 2. This condition arises from 
multiple factors, including metabolism, genetics, food intake and energy expenditure 
9,21. Both BDNF and T3 have been implicated in the etiology of obesity 30,35,37,82. 
BDNF haploinsufficient mice or mice with conditional depletion of BDNF in the 
brain after birth become obese 32,35.  BDNF modulates expression of thyrotropin 
releasing hormone (TRH) 52 in the hypothalamus, and neurons treated with T3 
suppress BDNF gene expression in the band of Broca 53.  Therefore, further 
characterization of T3 and BDNF interactions in the hypothalamus is needed. We 
propose that T3 decreases expression of BDNF, TRH and the primary signaling factor 
for BDNF, tyrosine kinase receptor B (TrkB), whereas BDNF protein acts 
reciprocally to increase gene expression for BDNF, TRH and TrkB.  
The expression levels of these two pathways correlate with development of the 
fat or lean phenotype in genetically selected Fat and Lean lines of chicken (Chapter 
3). We observed that BDNF levels are decreased in the Fat relative to Lean line at 
week 1, 3 and 5 of age, as well as increased T3 levels in the Fat line relative to the 
Lean line at weeks 1 and 3. This correlation suggested that interactions between the 
two pathways may modulate development of the phenotypes. Thus, we tested these 
interactions in primary hypothalamic cell culture (in vitro) and by directly treating 
embryos over 48-hours with T3 or methimazole (MMI), a thyroid hormone synthesis 




To test interactions of BDNF and T3 directly, we first assessed whether T3 was 
able to alter hypothalamic BDNF, TrkB and TRH gene expression and then 
determined whether BDNF was able to reciprocally modulate expression of these 
genes in vitro. Then we determined whether the BDNF protein or T3 could modulate 
expression of anabolic and catabolic gene expression in the hypothalamus, genes that 
are known to be associated with regulating energy homeostasis,  as well as genes 
identified via microarray analysis to be differentially expressed between the Fat and 
Lean lines. Finally, we treated chicken embryos during the last days of development 
with either T3 or methimazole, a thyroid synthesis inhibitor, in order to determine 
whether thyroid hormone is also able to modulate hypothalamic gene expression in 
vivo. 
Materials and Methods 
Dissections and neuronal cell culture 
Hypothalami were dissected in a saggital plane using the anterior commisure 
and the oculomotor nerve as neuroanatomical markers from day 20 chicken embryos, 
since they are primarily independent of myelination, which begins around embryonic 
day 14 but occurs primarily after hatch (5% myelinated in 3 day old chicks132). The 
brains were pinned to a dissecting tray and two sagittal were made, 1mm from the left 
and right side of the midline using a scalpel. (Fig 1 and 2). Primary hypothalamic 
neurons were cultured for 4 days, since neurons grown 4 days in vitro have not 
formed synaptic connections with other neurons, implying that data reflect mRNA 








neurons.  Dissections were conducted in Hanks Balanced Salt Solution 
supplemented with 10 mM HEPES and Sodium Pyruvate (.011 µl/mL). Cell culture 
plates were prepared prior to dispersing cells by coating them with poly-L-lysine 
(Sigma, P-6282, 10 µg/mL).  Neurons were dissociated in 0.05% trypsin in Minimum 
Essential Medium (SMEM), and cultured in Neurobasal medium supplemented with 





Fig 1. Hypothalamic dissection step 1. The black arrows indicate the location of the 
hypothalamus on a chicken brain. The brain was pinned to the dissecting tray in 
location distal to the arrows. The dashed lines indicated the initial scalpel cuts made 





























Fig. 2. Step 2 in the dissection of the hypothalamus. After the sagittal cuts on each 
side of the midline were made the slice was pinned on its side, as seen in the atlas 
above. A cut was made from the anterior commisure and the oculomotor nerve 
(diagonal line) and another cut made straight down from the anterior commisure133.  
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or 10 ng BDNF (Invitrogen) added 0, 1, 3, 6 or 24 hr prior to harvesting.  Cell 
viability was determined by staining with trypan blue. Cells were cultured for 4 days, 
since BDNF mRNA levels stabilized by day 3 in vitro (data not shown).  Cells were 
harvested with 0.05% trypsin, centrifuged and snap frozen in liquid nitrogen.  
RNA extraction and qPCR 
Cell culture RNA was extracted using RNeasy Mini kits (Qiagen, Valencia, 
CA). RNA was quantified using UV absorbance (260/280 nm) and with a bioanalyzer 
(Agilent Technologies, Palo Alto, CA), and Superscript III reverse transcriptase 
(Invitrogen) was used to create cDNA from 400 ng of RNA. Levels of mRNA for 
specific genes were quantified with Sybr green realtime qPCR master mix containing 
the following: 1unit of Taq, 20X SYBR green I, 400 nM fluoroscein, 10 mM dNTPs, 
25 mM MgCl2, 10X PCR buffer and water. Primers were designed with Primer 
Express (v2.0 Applied Biosystems) and the primer sequences previously described 
were used (Chapter 3).  
The qPCR output provided a Ct value for the threshold cycle. Data were first 
transformed to a ∆Ct value by subtracting the sample Ct value from the sample with 
the highest expression level in order to control for amplification efficiency. The ∆∆Ct 
value was then calculated by normalizing gene expression to two housekeeping 
genes, β-actin and GAPDH, using the geNorm software and methods 88.   
Methimazole and Thyroid Hormone treatment  
Chicken embryos were injected every 24 hours on embryonic day (e) 18 and 
e19 with 0.1 ml of 10-7 M T3, 0.075g/mL methimazole (a thyroid hormone synthesis 
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inhibitor) or a similar volume of water, and then hypothalami were collected on e20. 
To inject the eggs, a whole was gently drilled through the shell and the the whole was 
then covered with wax until the injection on the next day, with the wax being 
replaced each time. Hypothalami were dissected using a scalpel and neuroanatomical 
markers, the anterior commisure and the ventral portion of the oculomotor nerve.  
Statistical analysis and graphical display of data 
Differences in gene expression for all experiments were tested using a one-
way (cell culture treatment) analysis of variance (ANOVA) with a PDIFF post-hoc 
analysis to identify differences between the groups (Statistical Analysis System, 
v.8.02, SAS Institute, Cary, NC). Values reported are means ± SEM, and P <0.05 was 
required for statistical significance. All graphs were constructed using Graphpad 
(Graphpad Prism v.3.0, Graphpad Software). 
Results 
BDNF, TrkB and TRH gene expression 
Hypothalamic neuronal cultures were treated with 10-9M T3 or 10 ng/mL 
BDNF for 0, 1, 3, 6 and 24-hr and assayed with quantitative real-time PCR (qPCR) to 
determine BDNF, TRH and TrkB mRNA levels. Treating hypothalamic neurons with 
T3 suppressed expression of BDNF, TrkB and TRH mRNA relative to untreated 
controls (0-hr) (Fig. 3a, c and e, respectively).  Strikingly, treatment of neurons with 
BDNF modulated expression of the same genes in the opposite direction, relative to 
T3 treatment (Fig. 3b, d and f, respectively). β-actin was not different after either 
treatment (Fig. 3m, n). This indicated that T3 and BDNF act reciprocally to regulate 
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genes involved with their own signaling processes. Since LEPR is one gene known to 
modulate many other genes influencing body composition and food intake 8, we 
determined whether a similar pattern of gene expression would be seen. In fact, T3  
treatment suppressed LEPR gene expression after 1, 3, 6 and 24-hr (Fig. 3g), and 
BDNF treatment increased expression of the LEPR gene after 6-hr (Fig. 3h). This 
suggests that BDNF and T3 reciprocally modulate expression of a key gene in the 
obesity gene circuit. These data suggest that there is an interaction between BDNF 
and T3, which paralleled the data observed in the Fat and Lean lines (Chapter 3). 
Thus, we selected candidate genes differentially expressed between the lines in our 
previous studies to determine if mRNA levels are modulated by BDNF or T3 in vitro. 
Anabolic and Catabolic gene expression after T3 or BDNF treatment 
Given that T3 and BDNF reciprocally modulated catabolic gene expression for 
BDNF, TrkB, TRH and LEPR, we proposed that T3 would suppress the catabolic 
genes in our candidate gene list, POMC and CRH, and increase the anabolic genes, 
AGRP and NPY, whereas BDNF would have the opposite affect.  Indeed, T3 
suppressed POMC mRNA at 1 and 3-hours (Fig. 3i) and increased AGRP expression 
at 1 and 24-hours (Fig. 3k). However, BDNF had no effect on these genes (Fig. 3j and 






Figure 3. T3 and BDNF have opposite effects on hypothalamic genes known to 
regulate energy homeostasis in vitro.  a,c,e,g,i,k,m. T3 treatment decreased BDNF 
(a), TrkB (c), TRH (e), LEPR (g), and POMC (i) gene expression, increased 
expression of AGRP (k), but not β-actin (m) mRNA levels. (n=4-10). b,d,f,h,j,l,n. 
BDNF treatment increased gene expression of BDNF (b), TrkB (d), TRH (f), and 
LEPR (h) relative to control, but not POMC (j), AGRP (l) and β-actin mRNA levels 
(n) (n=4-6). Expression levels are normalized to a control value of 100%. * p<.05, 






Figure 4. Effects of T3 and BDNF on hypothalamic genes known to regulate 
energy homeostasis.  a,c,e. T3 treatment does not change CRH (a), NPY (c), and 5-
HTP (e) (n=4-10). b,d,f. BDNF treatment did not alter expression of CRH (b) or 
NPY (d), but did increase expression of 5-HTP(f) mRNA levels (n=4-6). Expression 




suggests that T3 directly suppresses expression of the catabolic gene, POMC, and 
increases expression of the anabolic gene, AGRP. BDNF was able to increase 
expression of most catabolic genes directly (BDNF, TrkB, TRH and LEPR), but 
indirect modulation of other genes, POMC and AGRP, may occur through BDNF’s 
ability to increase LEPR gene expression or TRH’s ability to modulate thyroid 
hormone levels and, thus, BDNF gene expression. 
The rate-limiting enzyme for neurotransmitter synthesis (5-tryptophan 
hydroxylase, 5-HTP) was differentially expressed between the Fat and Lean lines at 
week 5 of age. Interestingly, this profile correlated with TrkB expression at week 5 of 
age, which suggests that an interaction between the genes may be biologically 
relevant. As predicted, treating hypothalamic neuronal cultures with BDNF 
modulated 5-HTP gene expression. 5-HTP gene expression increased after treating 
cultures for 24-hr with BDNF (Fig. 4f), but no differences were observed after T3 
treatment (Fig. 4e).  Thus, the in vitro data indicate that BDNF modulates expression 
of 5-HTP.   
T3 and Methimazole treatment on anorexigenic and orexigenic neuropeptide genes in 
vivo 
We injected T3 or Methimazole (MMI), a thyroid hormone synthesis inhibitor, 
into the developing embryo and collected hypothalami on embryonic day 20. 
Interestingly, we observed similar patterns of expression for BDNF, TrkB and TRH 
(Fig. 5a-c, respectively) relative to cell culture data (Fig 3a, c, and e), but surprisingly 






Figure 5. T3 reciprocally modulates catabolic and anabolic genes.  a-f. T3 
treatment at embryonic day 18 and 19 had different effects on gene expression. T3 
suppressed BDNF (a), TrkB (b), TRH (c), and LEPR (d) gene expression, whereas 
methimazole increased BDNF (a), TrkB (b), and TRH (c), but not LEPR (d). T3 and 
methimazole both increased POMC (e) and had no affect on AGRP (f) mRNA. (n = 






respectively) and had no effect on AGRP (Fig. 5f). This suggested that T3’s ability to 
regulate anabolic and catabolic gene expression may be attributable to developmental 
or experimental parameters. 
Discussion 
Our data show that T3 decreased hypothalamic BDNF, TrkB, TRH and LEPR 
gene expression (Fig. 3a,c,e,g) and that BDNF reciprocally increased expression of 
the same genes (Fig 3b,d,f,h).  Additionally, we identified differential 5-HTP 
expression as another downstream factor modulated by BDNF that could also be 
involved in regulating the development of increased or decreased adipose state (Fig. 
4f).  T3 or Methimazole (MMI) injection resulted in a similar pattern of expression for 
BDNF, TrkB and TRH (Fig. 5h-i, respectively) as cell culture (Fig 3a, c, e), but 
surprisingly both T3 and MMI decreased LEPR, increased POMC mRNA levels (Fig. 
5j-k, respectively) and had no effect on AGRP (Fig. 5i). This suggested that T3’s 
ability to regulate anabolic and catabolic gene expression may be attributable to 
developmental, embryonic day 20 versus post-hatch day 29 (Chapter 5) or 
experimental parameters, intermittent delivery every 24 hours versus chronic delivery 
via an osmotic minipump (Chapter 5). Thus, we present a model summarizing our in 
vivo and in vitro data showing reciprocal regulation of gene expression by T3 and 







Figure 6. Model for BDNF and T3 interactions modulating body composition and 
metabolism. In vitro T3 inhibits BDNF, TrkB, TRH and LepR mRNA levels, 
whereas BDNF increases BDNF, TrkB, TRH, 5-HTP and LepR gene expression. Fat 
relative to Lean expression patterns in vivo support interactions presented in this 
model. In the Fat line, increased T3 levels may inhibit BDNF expression at wk 1 and 
3 and TRH at wk 3. In the Lean line increased BDNF expression may increase 
expression of TRH at wk 3, likely in conjunction with decreased T3, and TrkB, LepR 





T3 was also able to increase anabolic gene expression (AGRP, Fig. 3k and 5f) and 
decrease catabolic gene expression for the following genes in vivo and in vitro: 
BDNF, TrkB, TRH, LEPR and POMC (Fig. 3a, c, e, g and Fig. 5a-e). BDNF was able 
to directly modulate all catabolic genes in the opposite direction as T3, except POMC 
and AGRP (Fig. 3b, d, f, h, j).  Furthermore, it has been previously shown that LEPR 
signaling can suppress AGRP and increase POMC gene expression 134, and since T3 
and BDNF reciprocally modulate LEPR gene expression, they may indirectly 
modulate expression of both AGRP and POMC via LEPR. T3 was able to modulate 
expression of AGRP, but not NPY, although they are co-localized to the same cell 
type in the arcuate nucleus, suggesting that T3 is able to directly modulate expression 
via the promoter region of the AGRP gene. This mechanisms for gene expression is 
most likely not present in the promoter region of the NPY gene.  
To summarize our findings, we present a model summarizing our in vivo and 
in vitro data showing reciprocal regulation of the obesity gene circuit by T3 and 
BDNF (Fig. 6), suggesting that BDNF and T3 levels may explain how some 
individuals are more susceptible to develop an obese phenotype.  The primary 
locations in the hypothalamus modulating the effects presented in the model are the 
arcuate nucleus (ARC) and the paraventricular nucleus (PVN). AGRP is primarily 
expressed in the ARC and POMC is expressed in both the ARC and PVN. TrkB is 
colocalized with TRH in PVN neurons, with BDNF modulated TRH expression in 
this area via the TrkB receptor54. Although we utilized whole hypothalami in order to 
determine the effects of BDNF and T3, the specialized expression of these genes 
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suggests that the predominating effects presented in the model (Fig. 6) occur in the 
ARC and PVN.  
During the development of adiposity, it is plausible that interactions between 
T3 and BDNF serve to program an initial set point in order to establish long-term 
levels of body fat stores, possibly by regulating the maturation of homeostatic 
signaling circuitry (e.g. neural, hormonal or metabolic). For example, in the Fat and 
Lean animals, one mechanism altered during the development of adiposity could be 
initially signaled by T3 or BDNF (Chapter 3) and secondarily by a metabolic 
parameter, such as glucose utilization 90,117,135, lipolysis 136 or fuel partitioning 137. 
Currently, the rate of neuromodulator release in response to T3 or BDNF is unknown 
and may modulate neural circuitry more than protein or mRNA production. 
It is quite possible that interactions between BDNF and LEPR signaling may 
also modulate fat deposition and metabolism. LEPR is a key component in plasma 
leptin’s ability to modulate body composition. Furthermore, it has been demonstrated 
that LEPR gene expression in the brain is the primary signal that modulates body 
composition and not LEPR gene expression in the periphery138. In the mouse, leptin 
increases BDNF mRNA levels in the hypothalamus 139, and here we show for the first 
time that BDNF increases LEPR mRNA in the hypothalamus. In the Fat relative to 
Lean line, liver leptin levels are increased 1.7 fold 122, but a controversy about the 
validity of this identified chicken leptin sequence exists 123,140.  Regardless, the avian 
LEPR has been accurately sequenced 124. Thus, it is probable that BDNF and LEPR 
levels are modulating energy expenditure and energy balance to influence adipose 
deposition by modulating anorexigenic and orexigenic signaling networks in the 
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hypothalamus (Fig. 4). Therefore, it is not surprising that T3 acts in a reciprocal 
manner to inhibit BDNF and LEPR gene expression, potentially to compensate for 
changes in energy expenditure and ultimately establish a feedback loop. We propose 
that altered feedback may be an underlying mechanism regulating body fat stores.  
In conclusion, the balance between BDNF and T3 could modulate expression 
of genes that establish neuropeptide and hormonal signaling processes, which 
regulate long-term body fat stores. BDNF and T3 reciprocally modulate expression of 
the genes presented here, suggesting that expression levels may act as a fine tipping 
point for determining whether hypothalamic gene expression and adiposity increase 
or decrease over development. Thus, we propose that obesity therapeutics should 
simultaneously target BDNF and T3 to inhibit or reverse further fat deposition. 
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Chapter 5:  Differential effects of Glucocorticoids and 
Thyroid Hormone on Hypothalamic gene expression 
linked to a fat phenotype. 
Abstract 
Glucocorticoids and thyroid hormones modulate gene expression in the 
hypothalamus to regulate food intake and body composition 43. Under conditions of 
fasting, corticosterone (Cort) levels increase in order to increase blood glucose levels, 
and thyroid hormone levels decrease in order to preserve energy and decrease basal 
metabolic rate. Since the hypothalamus is the primary area of the brain known to 
modulate energy homeostasis  4,5, we sought to determine how triiodothyronine (T3) 
and/or corticosterone regulate anabolic and catabolic gene expression in the 
hypothalamus. Juvenile chickens were surgically implanted at 29 days of age with 
osmotic minipumps that delivered T3, Cort, T3 plus Cort, or a control vehicle for 72 
hours (n=4), since the chicken genome has more synteny with the human genome 
than a rodent species, such as the mouse 108,109. We show that Cort and T3 have 
overlapping roles in regulating many of the anabolic and catabolic genes, TRH, 
LEPR, and POMC, and that Cort and T3 have opposite effects on BDNF, NPY and 
AGRP. Putative transcription factor binding sites were identified that respond to both 
glucocorticoid and thyroid hormone located upstream of exon 1 in five of the 
anabolic and catabolic genes investigated. This suggests a plausible explanation for 
the complex interactions observed when hormone levels are elevated simultaneously 
or individually. We also identified for the first time a novel gene regulated by T3, a 
gene induced by tumor necrosis factor alpha (TNF AP), and a novel gene regulated 
by simultaneously elevated levels of Cort plus T3, zinc finger protein 36 (ZFP 36). 
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Collectively, these findings suggest that differentially expressed genes in the 
hypothalamus that contribute to increased food intake or obesity could be regulated 
by levels of T3 and/or Cort, which may serve to develop the neural circuitry to 
respond appropriately to reset or maintain energy homeostasis in the body. These 
interactions explain a potential homeostatic mechanism that links hypothalamic 




 Thyroid hormone and glucocorticoids regulate energy homeostasis and often 
act in opposition to one another. Increased levels of thyroid hormone decrease 
adipose tissue mass and increase food intake, whereas glucocorticoids have been 
shown to increase adipose tissue mass 43. These hormones have receptors in nuclei of 
the hypothalamus and modulate food intake and body weight by regulating 
transcriptional processes for anabolic and catabolic neuropeptides 77,141,142. Although 
it is known that thyroid hormone and corticosterone act in opposition to one another, 
with corticosterone (Cort) being considered an anabolic hormone and T3 a catabolic 
hormone, they have been shown to have synergistic effects when used in 
combination. For example, T3 treatment alone slightly enhanced protein synthesis in 
muscle, whereas Cort treatment increased protein breakdown and Cort in conjunction 
with thyroid hormone enhanced protein breakdown in muscle 6-fold 143. Under states 
of chronic stress, glucocorticoids have been shown to increase food intake which may 
be due to a dysregulation of normal mechanisms that modulate food intake 144. When 
glucocorticoid signalling is no longer effective, increased food intake mimics the food 
intake phenotype observed when thyroid hormone levels are elevated, however 
adiposity is still regulated in opposite directions. Therefore we wanted to determine 
which hypothalamic genes known to regulate both food intake and body weight are 
modulated in the same or different directions after chronic 72-hour treatment with 
Cort, T3, or Cort plus T3. 
 Previously, we demonstrated that thyroid hormone, T3, has been shown to 
modulate neuropeptide levels in the hypothalamus by increasing TRH, BDNF, TrkB, 
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and POMC gene expression and decreasing levels of AGRP mRNA in cell culture 
(Chapter 4). Cort levels are also able to modulate expression of these genes in the 
opposite direction by decreasing  AGRP and NPY expression and increasing POMC 
and BDNF  expression 55,69. Here we tested whether Cort, T3 or Cort plus T3 
treatments in vivo were able to reciprocally modulate 8 known anabolic or catabolic 
genes, as well as 6 candidate genes differentially expressed in Fat and Lean chicken 
lines (Chapter 2). The simultaneous delivery of Cort plus T3 will allow us to begin to 
determine which hormone has the predominant effect on regulating expression of 
each gene.  
Our results show that many of the predicted effects were present when Cort or 
T3 levels were increased individually, but surprisingly when levels of both hormones 
were elevated simultaneously the predicted effect was no longer present. This 
suggests that transcriptional mechanisms are altered by elevated T3 or Cort levels. 
Thus, we identified thyroid and glucocorticoid response elements in anabolic and 
catabolic genes and found that response elements for both hormones exist in the same 
region, suggesting an explanation for the complex gene expression patterns. Lastly, 
we identified one novel gene regulated by thyroid hormone, one novel gene regulated 
by T3 plus Cort only and verified in vivo one gene previously known to be regulated 
by Cort.  
Materials and Methods 
Animal and tissue preparation  
At 29 days of age, broiler chickens were given a subcutaneous implant of an 
osmotic minipump (Alzet® , model 2001; ALZA, Mountain View, CA) to 
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continuously release hormone for seven days at a rate of 1.0 µl/hour.  Corticosterone 
and L-tri-idothyronine (T3) hormones (Sigma Chemicals, St. Louis, MO) were 
dissolved in solutions of 50% DMSO and 50% propylene glycol, so as to deliver 600 
µg Cort/kg/day and 192 µg T3/kg/day, respectively. Animals were given ad libitum 
access to food and water at all times. The light/dark cycle was: 24 hr of light for the 
first two days and then 14 hr of light and 10 hr of dark thereafter.  
Animals were sacrificed after 72 hours of hormone or vehicle treatment, with 
the hypothalamus being immediately dissected and snap frozen in liquid nitrogen 
(n=4 for group) and stored at –80 ºC until further processing. All procedures were 
handled in accordance with the Institutional Animal Care and Use Committee at the 
University of Maryland and the University of Delaware. 
Primer design, validation and identification of GRE or TRE 
Primers were 18-30 nucleotides in length with a melting temp between 58-64 
ºC or 69-72 ºC and were designed using Primer Express (v 2.0, Applied Biosystems, 
Foster City, CA).  The primer product was between 100 and 150.  Forward and 
reverse primer sequences are listed in Table 1.   
Glucocorticoid and thyroid hormone response elements were identified using 
TESS software, Transcriptional Element Search System (University of Pennsylvania, 
1997, URL: http://www.cbil.upenn.edu/tess). Sequences were first identified in NCBI 
having the following annotations: AGRP: AB029443.1, BDNF: XM_419645.1, CRH: 




GENE Sense primer Antisense primer 
AGRP 5’AGAGCGGACCGTGAGGACACTT3’ 5’GTTGGCATTTCCTCCCAAAGGA3’ 
BDNF 5’TGGGTAACAGCAGCGGAGAA3’ 5’TATTGCTTCAGTTGGCCTTTAG3’ 
CRH 5’CACAGCAACAGGAAACTGATGGAAA3’ 5’AAAGAGGTGACATCAGAGCAGCACTATG3’ 
LEPR 5’AAAACCCAGAGCGTAGCGTCCAA3’ 5’TTGCTTACGCGATCGTTCACAAG3’ 
NPY 5’GGGAAAGCACAGAAAACATTCC3’ 5’AAATCCCATCACCACATCGAA3’ 
POMC 5’AGGGACCTCAGGGATCATCAA3’ 5’TGTTCAAGGGCAGGTTGGA3’ 
TRH 5’AGCATCTTTTGGAGACATTCAG3’ 5’CAGCTCCAGGTAGTTGACAAGGT3’ 
TrkB 5’GTCCTGGGTGCTCACTAACCTT3’ 5’TTATGGTTAACGAGGCAGGATTC3’ 




GHRHR 5’CCTTGGCATTCGGCTTTATTTAG3’ 5’TCAGGAAACAGTAGAGGAGTGCTACA3’ 
Β-actin 5’CCCAAAGCCAACAGAGAGAAG3’ 5’ACCATCACCAGAGTCCATCAC3’ 
Tabel 1. Primers for qPCR. 
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TrkB:  NM_205231, and TRH: XM_414458.1. The sequence was blasted to the 
chicken genome using Ensembl (URL: http://www.ensembl.org) and 1900 bp 
upstream of exon 1 for each gene was identified and searched for a GRE or TRE 
sequence. 
RNA isolation and cDNA preparation 
Individual tissue samples were homogenized and total RNA extracted 
according to manufacturer’s protocol with Rneasy Midi kit (Qiagen, Valencia, CA). 
RNA was quantified using UV absorbance (260nm) and 1µg total RNA was used to 
create cDNA using the stated protocol for Superscript III reverse transcriptase 
(Invitrogen, Carlsbad, CA) and an oligo(dT) primer. In order to have a negative 
control which measures genomic DNA contamination, cDNA was made that had no 
reverse transcriptase added. cDNA was diluted (1:20) and mRNA levels quantified 
using 2µl of cDNA  in a 20µl quantitative real time PCR (qPCR) reaction using a 
master mix that consisted of recombinant Taq, 2X PCR buffer containing 100 mM 
KCl, 20 mM Tris-HCl (pH 9.0), 0.2% triton-X 100, 3.8 mM MgCl2, 0.12 U/µl Taq 
Polymerase, 400 nM dNTPs, 40 nM fluorescein, and SYBR Green I Nucleic Acid Gel 
Stain diluted 1:10,000 (all Invitrogen, Carlsbad, CA)  and analyzed with the iCycler 
iQ Real-Time PCR Detection System (Bio-Rad, Hercules, CA).  A three-step PCR 
cycle protocol was used:  initial denaturation at 95 oC for 3 min, followed by 40 
cycles of 94 oC for 45s, 66 oC for 45s and 72 oC for 45s, followed by melting 
temperature analysis at 94 oC to verify that one PCR product was amplified.  
 
Statistical analysis and graphical display of data 
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 PCR products were verified by dissociation curve analysis and gel 
electrophoresis for the appropriate size.  The qPCR output data provided a Ct value 
for the threshold cycle.  The ∆∆Ct value was generated using geNorm software and 
methods 88.  Briefly, the data were first transformed to a ∆Ct value by subtracting the 
sample Ct value from the sample with the highest expression level in order to control 
for amplification efficiency. The ∆∆Ct value was then calculated by normalizing gene 
expression to β-actin.  
Differences in gene expression for all experiments were tested using a one-
way analysis of variance (ANOVA), and a fisher post-hoc analysis performed in 
order to determine interactions (Statistica, v6.0, StatSoft, Tulsa, OK, USA). Values 
reported are means ± SEM, and P <0.05 was required for statistical significance.  
 
Results 
72-hour Thyroid Hormone treatment 
In order to verify prior results from primary hypothalamic cell cultures (Chapter 
4), T3 was delivered via osmotic minipump for 72-hours. We demonstrated that T3 
was able to inhibit expression of catabolic neuropeptides TRH, BDNF, TrkB, LEPR 
and POMC (Fig 1a-e). We also found that T3 was able to increase expression of 
AGRP, an anabolic neuropeptide (Fig. 1f). Delivering T3 via osmotic minipump had 
no effect on NPY or CRH (Fig. 1g and h), as previously demonstrated in cell culture. 






Figure 1. Anabolic and catabolic gene expression in the hypothalamus after 72-
hour hormone treatment. a-h, Quantification of hypothalamic BDNF (a), TrkB (b), 
TRH (c), LEPR (d), POMC (e), AGRP (f), NPY (g), CRH (h) and β-actin (i) mRNA 




catabolic genes and increases expression of an anabolic gene. There was no change in 
β-actin gene expression after any of the treatments (Fig. 1i). 
72-hour Corticosterone treatment 
After treating chickens for 72-hours with corticosterone, we expected to 
observe the opposite effects as that seen with T3. Surprisingly, for many of the genes 
we observed a similar expression pattern as seen after T3 treatment. For example, we 
observed that Cort also inhibited expression of the catabolic neuropeptides TRH, 
LEPR and POMC (Fig 1a, d, and e). On the other hand, opposite to that observed 
with T3, Cort treatment increased expression of BDNF (Fig. 1b). Cort had no effect 
on TrkB or AGRP (Fig. 1c and f, respectively), and unlike T3, Cort increased 
expression of the anabolic neuropeptide NPY and decrease expression of the 
catabolic neuropeptide CRH (Fig. 1g and h).  
72-hour simultaneous delivery of Corticosterone and Thyroid Hormone 
Delivering Cort in conjunction with T3 had surprising effects on anabolic and 
catabolic gene expression in the hypothalamus. Similar to T3 treatment alone, T3 plus 
Cort decreased expression of TRH and BDNF mRNA (Fig 1a and b). Decreased 
POMC and increased AGRP expression had only a trend toward significance, which 
is surprising since T3 or Cort alone were able to decrease POMC mRNA levels and T3 
alone was able to increase AGRP mRNA levels (Fig. 1e and f).  Surprisingly, 
simultaneous treatment with Cort and T3 had no effect on TrkB, LepR and NPY (Fig 
1c, d and g, respectively). As predicted, Cort treatment, even in conjunction with T3 
delivery, suppressed expression of CRH (Fig. 1h). 
GRE and TRE identification in anabolic and catabolic genes 
Glucocorticoid and thyroid hormone response elements (GRE and TRE, 
respectively) were identified in the upstream region 5’ of the start site for anabolic 
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and catabolic genes differentially regulated by Cort and/or T3 treatment. Putative 
GREs and TREs were identified in the 2000 bp region upstream of exon 1 and were 
present in the following genes: AGRP, BDNF, CRH, LEPR, NPY, POMC, TRH and 
TrkB (Table 2). POMC was the only gene that did not have a TRE site in this region. 
BDNF contained the most TRE sites, and AGRP contained the most GRE sites, but 
regardless Cort treatment over 72-hours did not alter AGRP expression, suggesting 
that regulation of gene expression may occur prior to 72-hours or that the GREs sites 
in the AGRP gene simply are not functional. POMC was the only gene that did not 
contain a TRE, yet T3 treatment was able to suppress gene expression, suggesting that 
inhibition of POMC expression does not occur via direct interactions with T3, but 
more likely via another protein which is regulated by T3 expression or via a thyroid 
hormone receptor in the membrane 145. Five out of the eight genes (AGRP, BDNF, 
NPY, LEPR and TRH) had potential transcription factor binding sites for both the 
glucocorticoid and thyroid hormone receptors, perhaps providing an explanation for 
the gene expression pattern observed when the level of both hormones are elevated 
simultaneously.  
Candidate Genes 
 The following six candidate genes, differentially regulated in the 
hypothalamus of Fat and Lean lines (Chapter 2), were selected to determine if 
expression could be modulated by thyroid hormone, Cort or thyroid hormone plus 
Cort treatment: a gene induced by tumor necrosis factor alpha (TNFα AP), growth 
hormone releasing hormone receptor (GHRH-Rec), zinc finger protein 36 (ZFP 36), 
CCAAT/enhancer-binding protein (CEBP), and Metalloprotease 1 (ADAM12).  
TNFα AP decreased mRNA levels after T3 and Cort plus T3 treatment relative to 




GENE TRE # bp from 5’ 
start 
GRE # bp from 5’ start 
AGRP Yes 2 -1594, -1662  Yes 29 -147, -199, -251, -355, -381, -459, -537,  
-563, -589, -641, -756, -895, -951,  
-1035, -1051, -1147, -1156, -1230,  
-1267, -1360, -1499, -1594, -1606,  
-1630, -1659, -1778, -1800, -1833,  
-1892 
BDNF Yes 4 -26, -246, 
-1593, -1726 
Yes 24 -26, -139, -429, -468, -741, -898, -974,  
-1031, -1066, -1100, -1126, -1251,  
-1295,  -1319, -1368, -1405, -1446,  
-1500, -1518, -1593, -1664,  -1682,  
-1742, -1812 
CRH Yes 1 -1585 Yes 9 -22, -33, -61, -84, -163, -166, -1694,  
-1852, -1905 
 
LEPR Yes 3 -308, -997, 
-1420 
Yes 19 -67, -118, -308, -467, -495, -513, -530,  
-831, -839, -872, -895, -945, -955, -995, 
-1270, -1336, -1391, -1420, -1546 
NPY Yes 2 -981, -1133 Yes 14 -90, -151, -211, -277, -278, -370, -617,  




Yes 0 --- Yes 13 -314, -603, -636, -710, -781, -867, -976, 
-1017, -1088, -1167, -1522, -1740,  
-1914 
TRH Yes 3 -716, -921, 
-1652 
Yes 21 -85, -161, -239, -284, -319, -336, -469,  
-541, -802, -823, -921, -1032, -1066,  
-1241, -1290, -1299, -1350, -1615,  
-1684, -1696, -1885 




Table 1. Potential Glucocorticoid (GRE) and thyroid hormone response elements 
(TRE) located upstream of the 5’ start site for each gene. # indicates the number 
of potential GREs or TREs identified and the base pair number from the 5’ region of 







Fig 2. Candidate gene expression in the hypothalamus after Corticosteone or 
Thyroid Hormone treatment. a-c, Quantification of hypothalamic expression for 
TNF AP (a), GHRH receptor (b) and ZFP 36 (n = 4) by qPCR analysis. * p<0.05, 




with a trend toward suppression after Cort plus T3, but no change in mRNA levels 
after T3 treatment alone (Fig. 2b). ZFP 36 decreased expression in response to Cort 
plus T3 treatment, with unaltered mRNA levels after treatment with either T3 or Cort 
alone (Fig. 2c). There were no alterations in gene expression for CEBP, ADAM12, 
and TNF-ra2 after hormone treatments. 
Discussion 
 Our data suggest that Cort and T3 play overlapping roles in regulating mRNA 
levels in the hypothalamus for genes known to modulate food intake and body 
weight, specifically TRH, LEPR, and POMC. We also demonstrate that Cort and T3 
regulate gene expression in opposite directions, Cort treatment was able to increase 
BDNF expression, which was decreased by T3 treatment. Some genes are specifically 
regulated by one hormone only; NPY mRNA levels were increased by Cort whereas 
T3 had not effect on NPY, T3 decreased TrkB mRNA levels whereas Cort had no 
effect on TrkB expression, and T3 increased AGRP gene expression whereas Cort had 
no effect. Cort and T3 were able to modulate expression of AGRP and NPY, but in 
opposite directions. These effects correspond with increased Cort levels resulting in 
anabolic activity by increasing expression of the anabolic gene NPY. On the other 
hand, increased T3 levels generally increase catabolic activity, which would explain 
the downregulation of the anabolic gene AGRP.   
 Glucocorticoids are known to modulate adipose mass and food intake. 
Increased glucocorticoid levels decrease insulin and leptin, increase AGRP/NPY 
mRNA and decrease POMC gene expression in the hypothalamus 60. We show here 
that after 72 hours glucocorticoid treatment increased NPY levels, as predicted, but 
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no alteration in AGRP mRNA levels was observed, which suggests that AGRP might 
be sensitive to the duration of the treatment or that this is a species specific 
phenomenon.  In concordance with prior findings, we also demonstrated that POMC 
gene expression decreased in response to elevated Cort levels.  
 Thyroid hormones have been shown to decrease adipose tissue, and to 
compensate they also increase food intake. Elevated levels of thyroid hormone 
increase leptin levels as well as NPY mRNA and decrease Cocaine and Amphetamine 
regulated transcript (CART) and proopiomelanocortin (POMC) mRNA in the 
hypothalamus 55. We demonstrated that POMC gene expression was decreased after 
T3 treatment, but we show that there was no change in NPY mRNA levels, which was 
unexpected based on prior literature55. This suggests that our results might again 
demonstrate a species specific phenomenon or that, similar to AGRP after Cort 
treatment, alterations in NPY gene expression might be sensitive to the duration of 
the T3 treatment.   
Thyroid hormone and Cort modulate adiposity in the opposite direction but 
have been shown to increase food intake. Thus, we wanted to determine if treating 
with both Cort and T3 simultaneously would modulate gene expression patterns in a 
fashion that resembles the increase in food intake, or in the opposite direction similar 
to body weight. We have shown that BDNF gene expression is regulated in the 
opposite direction by thyroid hormone or Cort levels, but in conjunction T3 appears to 
have the predominating ability to decrease BDNF gene expression (Fig 1b). NPY 
mRNA levels were increased after Cort treatment, and no change was present after T3 
alone. However, when Cort and T3 were delivered together the presence of T3 was 
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able to ablate the increased gene expression observed with Cort treatment alone, 
suggesting again that T3 is the primary regulator for gene expression.  
Interestingly, identification of transcription factor binding sites revealed that 
BDNF has two sites and NPY has one site that potentially functions as both a TRE 
and GRE. If the GRE site induces transcription, it would be possible for T3 to inhibit 
transcription by competitively binding to the site, or perhaps binding with a higher 
affinity. TRH gene expression decreased in the presence of T3 or T3 and Cort, but 
there was only a trend toward decreased expression with Cort treatment alone, 
regardless of TRH having 1 out of the 2 TRE sites also identified as a GRE. However, 
it is quite plausible that this is not an active GRE or TRE site. LEPR was another 
gene having a putative transcription factor site that potentially serves as both a GRE 
and TRE. LEPR gene expression decreased in the presence of Cort or T3 alone, but 
the combination of the two delivered together only partially decreased expression. 
This could be due to the duration of hormone delivery, the possibility that expression 
patterns vary over time due to compensatory mechanisms, or the 2 out of 3 TRE sites 
that also function as a GRE. It is unknown whether these are excitatory or inhibitory 
response elements or functional in regards to transcription, but they do provide 
possibilities that deserve further investigation.  
Paradoxically, T3 inhibited POMC gene expression despite the lack of TRE 
sites upstream of exon 1. It has been shown that thyroid hormone receptors are 
located in the cell membrane and activate a MAPK signalling cascade 145, which 
could explain the decreased POMC mRNA levels observed. It is also possible that T3 
could increase expression of POMC mRNA by increasing expression of another, 
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unknown, protein. However, we observed that POMC mRNA levels increase after 
treating hypothalamic neurons in cell culture for 1 and 3 hours (Chapter 4), 
suggesting that the activation of thyroid receptors in the membrane is the more 
plausible explanation for T3’s rapid ability to modulate POMC gene expression.  
The results for TNFα AP and ZFP 36 identified them as novel gene targets for 
Cort and T3.  Previous work in the pituitary has shown that GHRH-receptor mRNA 
levels decrease in response to elevated levels of glucocorticoids 146,147, thus this was 
not surprising. The ability for thyroid hormone to modulate TNF AP has not been 
previously demonstrated, but interactions between thyroid hormone and TNFα 
signalling have been suggested. For example in humans with thyroid hormone 
resistance, it has been proposed that the increased circulating levels of thyroid 
stimulating hormone (TSH) might stimulate lymphocytes to secrete more TNFα 
which may cause TNFα to bind receptors on thyrocytes 148. Here we show that T3 is 
able to inhibit a gene induced by TNFα, perhaps as a feedback to prevent or limit 
TNFα signalling processes.  The results that Cort plus T3 treatment modulated ZFP36 
expression was quite surprising given that nothing has been previously reported about 
this interaction. Here we report for the first time that Cort and T3 suppress ZFP 36 
mRNA levels, but Cort or T3 treatment alone has no effect on ZFP 36 gene expression 
(Fig. 2c).  
Our findings demonstrate the finely orchestrated interactions between 
hormone levels and gene expression. Elevated levels of one hormone may not 
necessarily modulate gene expression in the same manner as it would if another 
hormone is simultaneously elevated. Here we begin to elucidate the underpinnings for 
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how hormone interactions may modulate anabolic and catabolic gene expression in 
the hypothalamus, with future work testing the functionality of the transcription factor 
binding sites identified that  include both a GRE and TRE being much deserved. 
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Chapter 6:  General discussion 
In this dissertation, novel mechanisms which may be linked to obesity have 
been identified. Fat and Lean lines that develop a 250% difference in visceral fat 
show differential genetic expression patterns in the hypothalamus. The Fat and Lean 
lines are a unique model because they dissociate the development of an obese 
phenotype from alterations in food intake, which often occur simultaneously. These 
lines also show alterations in thyroid hormone as well as anabolic and catabolic gene 
expression. Thus, we elucidate how hormone interactions regulate the hypothalamic 
obesity circuit. The specific aims were the following: 1) identify genes contributing to 
the fat or lean phenotype via microarray, 2) identify alterations in anabolic and 
catabolic gene expression in Fat and Lean lines, 3) verify direct interactions in cell 
culture and in vivo and 4) further characterize in vivo interactions by chronically 
delivering thyroid hormone and corticosterone (Cort) to determine whether anabolic, 
catabolic or candidate gene expression in the hypothalamus is modulated. 
 Three hypotheses were developed describing potential underlying 
mechanisms in the hypothalamus that modulate body composition. The following two 
key processes were identified via microarray technology in the Fat and Lean chicken 
lines: genes involved with glycolysis have been associated with Klotho, ADAM12 
and DRP2 (Table 1c and Fig. 6b, Chapter 2) and a gene induced by TNFα, TNF AP, 
has been identified to be associated with other genes previously known to regulate the 
obese phenotype, for example CEBPζ (Table 3 and Fig 6a, Chapter 2). We were also 
able to identify potential biological links between many other genes known to 
regulate obesity. From this we were able to identify for the first time which catabolic 
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and anabolic genes are associated with the development of adiposity independent of 
food intake alterations (Chapter 3). This identification is quite important because it 
begins to untangle the polygenic nature of diseases associated with body composition.   
 Another hypothesis developed and tested demonstrated that that Brain-derived 
Neurotrophic Factor (BDNF) and T3 are able to reciprocally modulate the obesity 
gene circuit in the hypothalamus by regulating expression of many anabolic and 
catabolic genes. Using the Fat and Lean line data, we selected candidate genes that 
were differentially expressed between lines. Since the Fat line has increased T3 levels 
relative to the Lean line at weeks 1 and 3 of age and since BDNF mRNA levels are 
decreased in the Fat relative to Lean at week 1, 3 and 5 of age, we tested whether 
BDNF or T3 were directly able to modulate expression of candidate genes (Chapter 4 
and 5). We tested these interactions in primary hypothalamic cell culture (in vitro) 
and by directly treating embryos over 48-hours with T3 or methimazole (MMI), a 
thyroid hormone synthesis inhibitor, or by treating animals 29 days of age with an 
osmotic minipump that delivers T3, Cort or T3 plus Cort for 72-hours.   
We observed that BDNF and T3 reciprocally modulate some of the anabolic and 
catabolic genes differentially expressed in the Fat and Lean lines, suggesting that this 
may be a mechanism that regulates the divergence of adiposity between the lines. Our 
data show that T3 decreased hypothalamic BDNF, TrkB, TRH and LEPR gene 
expression and that BDNF reciprocally increased expression of the same genes (Fig 
1, Chapter 4). We present a model summarizing our in vivo and in vitro data showing 
reciprocal regulation of gene expression by T3 and BDNF (Fig. 4, Chapter 4). Fat and 
Lean line data demonstrated that BDNF or T3 levels could serve as the primary 
signalling factor to initiate hypothalamic gene expression during the different stages 
of adiposity development. Corresponding with predictions presented in our model 
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(Fig. 4, Chapter 4), before and at the onset of adiposity divergence (week 1 and 3), 
plasma T3 was increased and hypothalamic BDNF expression was decreased in the 
Fat relative to lean line (Fig 1, 2 and 3, Chapter 3). An interaction between BDNF 
and T3 was also demonstrated in vitro (Chapter 4). Additionally, at week 3 
hypothalamic TRH mRNA levels were lower in the Fat relative to the Lean line, 
which also corresponds to in vitro experiments, suggesting that either T3 could inhibit 
expression of TRH in the Fat line or increased BDNF expression in the Lean line 
could increase expression of TRH (Fig. 1, Chapter 4). Finally, at week 5 of age, 
hypothalamic BDNF levels continued to increase in the Lean relative to Fat line, 
which corresponds to an increase in TrkB, LEPR and 5-HTP levels that were also 
shown in vitro (Chapter 3 and 4).  It is still unknown whether BDNF or T3 initiates 
the differential gene expression for TRH, TrkB, LEPR or 5-HTP. In summary, our 
data support a novel pathway that contributes to differences in visceral fat 
independent of environmental alterations. 
Utilizing the microarray data from Fat and Lean lines, candidate genes were 
selected (Chapter 2) and for the first time we show that expression of these genes is 
modulated by T3 and/or glucocorticoids (Chapter 5). We found that delivery of 
glucocorticoids for 72-hours via osmotic minipump suppresses GHRH receptor gene 
expression in the hypothalamus, which has been previously demonstrated in the 
pituitary. We have also shown that T3 delivery for 72-hours via minipump suppresses 
a gene induced by TNFα (TNF AP), a gene previously not known to be modulated by 
thyroid hormone. Lastly, we have shown that the Cort and T3 together suppress ZFP 
36, with either hormone alone having no effect on mRNA levels. The interaction 
between ZFP 36 and these hormones has never been shown or suggested. This is an 
important association since it is possible that ZFP 36 could regulate expression of 
genes involved in glycolysis (Chapter 2). This implies a possible mechanism for how 
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increased levels of glucocorticoids and thyroid hormone may modulate glucose 
metabolism, at least within the hypothalamus.  
In summary, we have demonstrated that BDNF and T3 reciprocally modulate 
expression of many genes, suggesting that expression levels may act as a fine tipping 
point for determining whether hypothalamic gene expression and adiposity increase 
or decrease over development. The implications of this are huge, since thyroid 
hormone supplements are commonly given to treat thyroid hormone disorders, which 
may disrupt the balance between BDNF and T3 signalling and ultimately disrupt 
expression of many genes in the hypothalamus that serve to maintain energy 
regulation within a healthy range. Thus, we propose that obesity therapeutics should 
simultaneously target BDNF and T3 to inhibit or reverse further fat deposition.  
We have also identified a possible link between many genes known to regulate 
body composition, suggesting that new drug developments should be designed to 
modulate expression of all these genes simultaneously, to prevent dysregulation of the 
system or negative compensation. Here we show that it is not BDNF or T3 alone 
causing the divergence of adiposity between the Fat and Lean lines, but it may also be 
genes involved with glycolysis as well as many other genes not modulated by T3 
levels. Thus, we present here multiple hypothalamic gene networks that may 
simultaneously be modulating the phenotype, potentially through alterations in 
hormone levels. For example, elevated levels of both Cort and T3 are able to decrease 
expression of many genes identified by the microarray (Chapter 2), specifically a 
gene induced by TNFα, ZFP 36 and these hormones had a trend toward decreasing 
levels of GHRH receptor. We also have shown that elevated levels of both Cort and 
T3 decrease expression of TRH, BDNF and CRH, with a trend toward suppression for 
POMC and a trend to elevated levels for AGRP gene expression. Please note that 
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these “trends” toward decreased or increased expression may be priming the system 
to respond more quickly when one hormone becomes the dominantly expressed 
hormone relative to the other one, since the genes were responsive to elevations in 
just one hormone. In conclusion, the finely orchestrated expression between hormone 
levels and hypothalamic gene expression modulate physiological processes to express 
either a fat or lean phenotype. We have shown that these hormones alter more than 
one hypothalamic gene network simultaneously, thus demonstrating the complexity 





α-melanocyte-stimulating hormone (αMSH) 
Agouti-related protein (AGRP) 
AMP-activated protein kinase (AMPK) 
Brain-Derived Neurotrophic Factor (BDNF) 
CCAAT/enhancer-binding protein (CEBP) 
Cholecystokinin-B receptor (CCKr) 
Cocaine- and amphetamine-regulated transcript  (CART) 
Corticosterone (Cort) 
Corticotropin releasing hormone (CRH) 
Cytochrome b (Cyto b) 
Dihydropyrimidase protein-2 (DRP2) 
Elongation factor 1 α (EF1α)  
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
Growth hormone releasing hormone receptor (GHRHR) 
Induced by TNF alpha (TNF AP)  
Leptin Receptor (LEPR) 
Melanin concentrating hormone, MCH 
Melanocortin-4 receptor (MC4R) 
Metalloprotease 1 (ADAM12) 
Neural Enolase (Neuro Eno) 
Neuropeptide Y (NPY) 
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No description (ND) 
Orexin (ORX) 
Phosphoglucose isomerase (Phosg isomerase) 
Phoshpoglycerate mutase (Phosg mut) 
Pro-opiomelanocortin (POMC) 
Soluble NSF-attachment protein (SNAP α) 
Sparc/osteonectin (SPOCK2) 
Thyroid stimulating hormone (TSH) 
Thyrotropin releasing hormone (TRH) 
Triiodothyronine (T3) 
Thyroxine (T4) 
TNF receptor associated factor 1 (TRAF-1) 
TrkB tyrosine protein kinase receptor (TrkB) 
Tumor necrosis factor α (TNFα) 
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